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DEVELOPMENT OF BIOANALYTICAL METHODS FOR CLINICAL 
APPLICATIONS AND DRUG SCREENING 
 
XIAOHAN CAI 
 
ABSTRACT 
 
In the past decade, bioanalytical method development has become an integral part of 
clinical diagnosis, biomarker discovery, and drug discovery and development. The new 
and emerged bioanalytical technologies allow the quantitative and qualitative analysis of 
small molecules and biomolecules with high sensitivity and specificity. Specifically, the 
bioanalytical methods based on LC-MS and methylation-specific PCR are well suited for 
detecting low-abundance metabolites, proteins, and DNA in biofluids and tissues for 
biomarker investigation. They offer great clinical promises for early diseases diagnosis 
and therapeutic interventions. Besides, the LC-MS/MS quantitative method is essential 
for the estimation of pharmacokinetic and toxicological properties in drug screening. 
 
In this work, modern bioanalytical technologies, together with their applications from 
biomarker discovery and validation in metabonomics, genomics and proteomics to drug 
discovery, were reviewed. Dependent on the type of molecules analyzed, different 
methods were established to achieve accurate and reliable detection. LC-MS/(MS) 
methods were developed and validated for quantitative analysis of bile acids and anti-
cancer agent JCC76. The former has been successfully applied in a clinical study for the 
 vi 
diagnosis of inflammatory bowel diseases; and the latter has been utilized in a 
pharmacokinetics study for drug screening and optimization. In terms of proteomics 
profiling, a LC-MS/MS method was demonstrated for comparative analysis of serum 
peptides with the successful identification of a potential biomarker for ovarian cancer. 
Lastly, a comprehensive DNA methylation profiling for hepatocellular carcinoma was 
conducted through methylation-specific PCR methods. These methods enabled sensitive 
and specific detection of DNA hypermethylation on several tumor-associated genes.  
 
In addition, this work discussed a major challenge of matrix effect in quantitative method 
development. Possible solutions were proposed for matrix effect prevention and 
troubleshooting. Moreover, standard addition coupled with internal standard method and 
optimizing sample extraction method was illustrated for compensating or minimizing 
matrix effect in chapter II and chapter III, respectively.  
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CHAPTER I 
 
 
INTRODUCTION OF BIOANALYTICAL METHODS FOR CLINICAL 
APPLICATIONS AND DRUG SCREENING 
 
 
1.1. General introduction of bioanalytical methods and their applications 
 
Bioanalytical science, with a focus on qualitative and quantitative measurements in 
biological materials, plays a key role in understanding diseases, clinical diagnosis, and 
drug discovery and development. The technologies in biomedical science have made 
significant progress over recent years. This facilitates bioanalytical method development 
to become an integral component of biomarker discovery, drug 
metabolism/pharmacokinetic (DMPK), and toxicological monitoring. Advanced 
technologies and enhancements of conventional platforms emerged from bioanalysis 
fulfill the requirements of clinical and pharmaceutical fields, including the improvement 
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in mass spectrometry detection, fast chromatographic separation, high-throughput sample 
pretreatment, and melting curve analysis with high resolution for genomic assays. 
 
Early diagnosis of diseases has great significance in improving survival rates and 
minimizing current invasive diagnostic procedures. This leads to another major clinical 
need in the accurate detection of molecular biomarkers for chronic illnesses and cancers. 
The biomarker study monitors different biological entities including nucleic acids, 
proteins, and metabolites to reflect the pathophysiology and progression of diseases. Ideal 
biomarkers need to be well-understood for their functions in the pathogenic processes and 
their values for clinical diagnostic, prognostic, and predictive outcomes. However, these 
molecular biomarkers often present in low abundance in the biological samples, bringing 
great challenges in reliable detection and validation. Although these challenges remain, 
there is a large number of biomarkers developed currently and to be assessed in clinical 
studies for their diagnostic and prognostic applications [1]. 
 
Besides the broad bioanalytical applications in biomarker discovery, the impressive 
growth of quantitative bioanalysis has been also well-documented in pharmaceutical drug 
discovery and development. In the past decade, more than 500 novel drugs were 
approved by U.S. Food and Drug Administration (FDA) to prevent and treat human 
diseases [2]. Each year, more than 3000 on-going clinical trials are carried out in the drug 
development phase [3]. Despite the enormous amount of lead compounds screened in the 
drug discovery phase, the drug development process is costly and risky with very low 
rate of clinical success. This drives the rational lead optimization in the earliest stage of 
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drug discovery to improve the likelihood of drug approval and to prevent drug 
withdrawal on the market. Quantitative bioanalysis serves as a major tool for 
understanding pharmacological properties including absorption, distribution, metabolism, 
and elimination (ADME), as well as toxicity to guide the drug screening for lead 
candidates. 
 
1.1.1. Clinical applications for biomarker studies 
 
Biomarkers are defined as indicators of normal biological processes, pathogenic 
processes, or pharmacological responses to a therapeutic intervention according to the 
National Institutes of Health (NIH) working group [4]. Cancers are the most studied 
diseases for biomarker discovery since the early detection of cancers before metastasis is 
always desirable to greatly improve survival. With advanced technologies for molecular 
biomarker measurement, thousands of potential biomarker candidates have been 
discovered and linked with cancers. These disease-related molecules may involve in cell 
regulatory and post-translational modification processes as proteins, alter the expression 
of downstream target molecules as nucleic acids, and represent metabolic responses as 
endogenous small molecules.  
 
Among different biomarker discovery tools, proteomics allows the identification, 
characterization, and quantification of differential protein expression involved in normal 
and pathological states.  Blood is the most commonly used sampling source for proteome 
profiling since blood sampling is non-invasive compared to tissue biopsy. In cancers, the 
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intra- and inter-cellular events happen at the tumor tissue microenvironment, introducing 
the changes of accumulative protein expression in the circulating blood stream. The 
differentiated proteomic pattern may reflect the development of malignancy and can also 
provide diagnostic, prognostic and predictive value for cancers. Extra-cellular nucleic 
acids in biofluids is another popular source of biomarker investigation, since it can reflect 
the cancer cell transformation induced by gene mutation or hypermethylation [5]. The 
circulating free DNA and cancer-specific RNA have been profiled in numerous genomic 
biomarker studies for the diagnosis and staging of cancer diseases. 
 
The epigenetic changes in DNA methylation are also commonly associated with 
tumorigenesis.  Taking place in the promoter region of CpG islands, the methylation of 
cytosine residue in normal cells is well-maintained in a homeostasis through a feedback 
regulation of DNA methyltransferase mechanism [6].  The disturbances to normal 
cytosine methylation are fundamental contributors to the malignancy of cancer [7]: the 
hypermethylation of tumor suppressor genes results in the inactivation of gene 
transcription and thus the loss of their intrinsic functions; global change of 
hypomethylation in a wide area causes repeated sequences and transposable elements, 
ultimately resulting in the loss of genomic stability and increased mutations [8]. These 
aberration events are the rationales for discovering potential genomic biomarkers to aid 
the diagnosis, predict the clinical outcomes, and subsequently guide the therapeutic 
treatment. Therefore, it is of crucial importance to develop bioanalytical tools that 
support the profiling of aberrant methylation.  
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Besides the large biomolecules in cancer biomarker study, the endogenous metabolites in 
cells, tissues, and body fluids start to gain more interest for reflecting human health status 
from their quantitative information. The most common example in clinical application is 
the measurement of cholesterol to monitor the cardiovascular disease by physicians. The 
metabolic signatures of patients reflect the biochemical changes in diseases and the 
disturbed metabolic pathways.  The analysis of glycerophospholipids, fatty acids, steroid 
metabolites, and bile salts have been conducted for examining abnormal lipid metabolism 
and interaction of intestinal microflora for liver and intestinal diseases. These research 
areas provide useful sources for metabolic biomarker profiling. 
 
1.1.2. Bioanalysis applications in drug discovery and development 
 
Drug PK and toxicity properties are key parameters in the screening and optimization of 
lead compounds in the drug discovery phase. An ideal drug candidate should demonstrate 
the ability be absorbed in the blood stream, reach desirable concentration for effective 
activity, and be eliminated without producing toxic metabolites. 
 
High-throughput PK screening usually starts from in-vitro assays to study the drug-drug 
interaction and metabolism using liver microsomes and hepatocytes as experimental 
systems. However, the in-vitro results cannot truly represent the real physiological 
environment and may lead to mistaken conclusion about drug metabolism. Therefore, it is 
essential to assess the PK parameters in vivo to improve the candidate selection through 
animal models.  
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In order to accurately define the drug behaviors in vitro and in vivo, bioanalytical support 
has been a prerequisite in the pharmaceutical industry. The large amount of compounds 
involved in the lead optimization requires the quantitative method to be accurate, 
sensitive, and high-throughput to facilitate drug discovery. These requirements can be 
fulfilled by accurate sampling procedures, advanced chromatographic and mass 
spectrometric techniques, as well as automated sample preparation methods. 
 
1.2. Modern bioanalytical technologies 
 
Modern bioanalytical technologies have been significantly broadened in the last decade, 
demonstrating its ability in accurate qualitative and quantitative determination for 
protein, nucleic acids, small molecular metabolites, and drugs in biological materials. The 
major methodologies used for proteomics investigation are based on mass spectrometry 
(MS). The dramatic progresses of MS instrumentation refine mass accuracy, resolution, 
and dynamic ranges, ensuring the successful detection of low abundance proteins in 
biofluids and structural confirmation with their characteristic precursor and fragment 
ions.  In addition, the robust and reliable liquid chromatography (LC) system in low flow 
rate has greatly improved the sensitivity for the MS detection and confidence for 
structure illustration.  
 
Besides its application in protein analysis, the hyphenation of LC and MS (LC-MS) is 
established as the state-of-the-art methodology for the quantitation of small molecular 
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compounds due to its specificity and sensitivity. It is now widely accepted as the 
preferred method for the quantitative measurement of small molecule drugs and 
endogenous metabolites in various biological matrices including plasma, serum, blood, 
urine, intestinal fluid, and tissue.   
 
With respect to epigenetic biomarker discovery, the majority of DNA methylation assays 
are based on bisulfite reaction, methylation-specific PCR (MSP), and melting curve 
analysis. Sodium bisulfite converts cytosine to uracil at unmethylated CpG site, leaving 
methylated one unchanged. The MSP methods with designed primers selectively amplify 
methylated DNA, bringing high analytical specificity and sensitivity.  
 
1.2.1. Principles of LC-MS 
 
1.2.1.1. LC separation 
 
LC is the basic separation platform for bioanalysis. With this technique, target analyte 
can be separated with interfering protein, salts, and phospholipids content in complicated 
biological materials. The separation mechanisms of liquid chromatography are based on 
the distribution of analyte between the liquid mobile phase and a stationary phase. 
Depending on different type of stationary phases, different distribution mechanisms are 
applied.  
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Adsorption mechanism is applied for both normal-phase (NP) chromatography and 
reverse-phase (RP) chromatography. In NP chromatography, the stationary phase is a 
polar silica gel and the mobile phase is a non-polar solvent such as hexane, pentane, and 
chloroform. NP chromatography is preferable for non-polar analyte and the retention 
decreases as the non-polarity of analyte increases. Opposite to NP chromatography, the 
stationary phase of RP chromatography uses non-polar silica based packing materials 
after the surface modification with C8, C18, or phenyl. Accordingly, the retention 
decreases with increasing polarity of the compound and the amount of polar solvents. RP 
chromatography is suitable ideally for polar and ionic compounds, which makes it the 
most widely used LC application. The interaction of analyte with stationary phase and 
mobile phase solvent greatly depends on the hydrophobicity of the analyte.  
  
Ion-exchange chromatography is based on the ion exchange equilibrium between the 
ionic or polar compounds with the stationary phase. With opposite charge with the ionic 
functional group of the stationary phase, the ionic compounds can be retained. The 
elution speed is related with the ionic strength of the counter-ions, pH environment, and 
the modifier contained in the mobile phase.  
 
Size-exclusion chromatography is usually applied in the separation of macromolecules 
according to their ability to penetrate into the pores of stationary material. The elution 
time of analyte is merely based on their size, but not molecular weight. The retention 
decreases as the size increases. 
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Besides the aforementioned traditional chromatography, there are some modern 
approaches for improving chromatographic resolution and separation efficiency: ultra-
performance liquid chromatography (UPLC), monolithic chromatography, and 
hydrophilic interaction chromatography (HILIC). Underlying the same basic principle 
with RP-LC, UPLC utilizes column with sub-2 μm particle size and a system that can 
handle elevated pressure. UPLC has great advantages in resolution, sensitivity, and speed 
over conventional HPLC, and thus is considered as a better tool for high throughput 
analysis. Monolith column is packed with highly porous material, which is designed to 
handle fast flow rate and ensure sufficient surface for separation at the mean time. 
Consequently, the separation speed and sample throughput are significantly increased. 
HILIC is a valuable alternative to NP chromatography for very polar compounds because 
polar compounds are hardly retained and experience bad reproducibility when using NP 
chromatography. In addition, the large portion of organic mobile phase used for the 
HILIC elution increases the sensitivity when coupling MS with LC for detection.  
 
In general, a sample is separated and analyzed by LC in the following sequence: the 
sample solution is injected through an injection port, and then delivered by the mobile 
phase by high-pressure pumps, and finally flowed into the column for retaining and 
further elution (Fig. 1.1). The instrumentation design should consider the following issues: 
the high-pressure is generated when the solvents are pumped into the small particle filled 
stationary phase; the dead volume of connecting tubes, the injector, and the mixing valve 
should be minimized to prevent the reduction of analyte peak resolution; the sample 
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residue on the tubing and injector should be avoided for carry-over issue in quantitative 
analysis. 
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Figure 1.1, The instrumentation setup for LC separation 
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In this work, all small molecule compounds and peptides were separated by RP-LC with 
a C18 column and mass spectrometric detection. A guard column was used to prevent 
potential damages from the injected crude samples and proteins from the biological 
matrices. As the heart of LC system, the column needs to achieve adequate separation 
with a short time, maintain the precision for the retention, and have good stability in a 
broad pH range. 
 
1.2.1.2. MS detection 
 
MS has become a crucial part for pharmaceutical analysis and biomolecules research 
because of the improvements in ionization methods in the past decade. Taking 
advantages of powerful separation and sensitive detection, LC-MS analysis is well-suited 
for structural elucidation, accurate quantification, and metabolites prediction in complex 
biological matrices. The analyte in liquid flow eluted from the LC goes into three 
modules of ionization source, mass analyzer, and detector, undergoing ionization and 
evaporation, separation, and detection, respectively.  
 
As the basic interfacing strategy, atmospheric-pressure ionization (API) enables the MS 
analysis by generating ions in a steam of liquid after LC separation. A number of API 
sources such as electrospray (ESI) and atmospheric-pressure chemical ionization (APCI) 
were developed to transfer the analyte from the liquid phase to the gas phase in MS with 
different ionization mechanisms. 
 
 13 
In the ESI source, a highly positive or negative voltage is applied to the end of a steel 
capillary probe, where the sample solution is introduced (Fig. 1.2). When traveling along 
the capillary probe, the sample liquid is sprayed with excess charge. The nebulization 
process helps the formation of small droplets for ions in solvent vapor. During their flight 
from the electrical field to the MS proper, the droplets pass through an evaporation 
chamber, allowing the evaporation of solvents with the help of heating gas and 
nebulization gas. In the mean time, the quick evaporation process condenses the droplets 
and increases the surface charge density. At the end of the evaporation, the light solvent 
molecules diffuse away, leaving ions to enter into the MS analyzer. 
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Figure 1.2, The schematic diagram of ESI source 
(http://www.ucl.ac.uk/ich/services/lab-services/mass_spectrometry/metabolomics/hplc) 
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Unlike ESI, the ionization process of another liquid-based ionization source APCI occurs 
in gas phase. Without applying high voltage, the APCI capillary enables the volatile 
liquid sample to be heated and spayed first, and then a corona discharge needle with a 
high voltage generates ions from the aerosol cloud through interaction of reagent gas and 
electrons. 
 
When ions are accelerated by the applied electric or magnetic field, the mass analyzer 
separates the ions according to their mass to charge ratio (m/z). Typical mass analyzers 
include quadrupole MS, ion-trap MS, and time-of-flight (TOF) MS with their own 
characteristics and applications.  
 
The quadrupole instrument selects ions with a certain m/z to pass through the four 
parallel rods with certain direct-current potential and radiofrequency. Triple quadrupole 
MS allows the filtration of incoming ions by the first quadrupole, the fragmentation of 
selected ions by the second quadrupole, and the filtration of selected fragments by the 
third quadrupole, achieving high specificity. Similar to quadrupole MS, the ion-trap MS 
captures ions by a three dimensional manner in the electrical and magnetic combined 
fields (Fig. 1.3). The ion-trap MS takes advantages of its high sensitivity and resolution. 
The TOF MS accelerates ions and determines the flight time needed for ions moving 
from the ion source to the detector. TOF MS is characterized with advantages in high ion 
transmission and unlimited mass range, but with disadvantages in precursor ion 
selectivity. The modern MS instrument hybridizes different type of MS analyzers on one 
instrument, facilitating broader MS/MS applications. 
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Figure 1.3, The operation of quadrupole MS and ion-trap MS 
(www.currentseparations.com/issues/16-3/cs16-3c.pdf) 
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1.2.2. Quantitative LC-MS(/MS) analysis for small molecules 
 
The most prevalent method for small molecules quantification is based on quadrupole 
MS with ESI or APCI interface since 1990’s. The detection of target analyte ions utilizes 
selective-ion-monitoring (SIM) and multiple-reaction-monitoring (MRM) approaches for 
LC-MS and LC-MS/MS methods, respectively.  
 
The SIM mode detection is operated on single quadrupole instrument, with a particular 
m/z value selected for the target analyte ion. Because the impurities including proteins, 
phospholipids, and salts in the sample matrices may have the same m/z with target 
analyte, the LC-MS analysis requires more elaborate sample extraction and LC separation. 
Compared with SIM, MRM detection is more specific and sensitive since triple-
quadrupole (QqQ) MS analyzer is applied for ion filtration and collision. Particular 
precursor ion and product ion are selected for detection based on their unique 
fragmentation pathway, resulting in a great improvement of signal to noise ratio (S/N) 
comparing to that of SIM.  
 
The quantitative LC-MS(/MS) method development generally follows the workflow in 
Fig. 1.4. A successful bioanalytical method requires three interlinked methodologies in 
MS detection, chromatographic separation, and sample preparation. Some important 
aspects and challenges such as mobile phase choice, sample pretreatment, and matrix 
effect are discussed in the following sections.  
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Figure 1.4, Method development workflow for small molecule bioanalysis 
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1.2.2.1. Mobile phase optimization 
 
Mobile phase additives are often added in RP-LC for reproducible retention and the 
improvement of resolution and sensitivity when using MS as a detector. However, only 
volatile additives are compatible with LC-MS, because the non-volatile buffers such as 
phosphates may clog the ionization source and cause signal suppression.   In addition, 
some volatile additives help the retention but deteriorate the MS ionization. For example, 
trifluoroacetic acid (TFA) is commonly used as an ion-pairing agent for increasing the 
retention of polar compounds. Nevertheless, it is also reported to induce significant signal 
suppression for some negatively and positively charged compounds [9-11].  
 
Besides the LC modifiers, the pH of the mobile phase also has a large impact on both 
retention and ionization. By adding volatile acids such as formic acid, acetic acids, and 
their salts with ammonium in the mobile phase, the protonation of basic molecules under 
positive ionization mode is favored in acidic condition. Similarly, the deprotonation of 
some acidic molecules in negative-ion mode can increase the response by adding 
ammonium hydroxide as mobile phase additive. But these conditions may cause an 
adverse effect for retention if the hydrophobic interaction between analyte ions with the 
stationary phase is not sufficient [12]. In addition, the concentration of the additives is 
also critical since the MS response may be reduced under very high concentration, but 
concentration that is too low may lack buffer capacity. To solve the dilemma between 
retention and ionization, the selection of mobile phase composition needs to carefully 
consider all the characteristics of individual analyte. 
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1.2.2.2. Sample preparation 
 
Although LC is a powerful tool for separation, the sample pretreatment for biological 
sample before injecting to LC-MS is essential for accurate and reproducible analysis. The 
biological sample matrices are very complicated with much higher content of proteins, 
salts, and endogenous lipids than target analyte. The large protein content in plasma 
sample is problematic due to its clogging of column and reducing analytical efficiency. 
Also, the endogenous interference and salts in most biological samples may suppress the 
ionization of analyte.  
 
Conventionally, the sample cleanup has been performed by protein precipitation (PPT), 
liquid-liquid extraction (LLE), and solid phase extraction (SPE). PPT is popular when 
handling plasma sample because it is simple and fast. But the major disadvantage for PPT 
is that residues consisted of salts and endogenous material after the removal of proteins, 
which may greatly affect the MS detection [13]. Besides the use of organic solvents for 
denaturing proteins, other PPT additives such as acids, metal ions, and salts were reported 
to improve the efficiency of protein removal and disrupt the protein-drug binding [14].  
 
LLE is an efficient technique to separate analyte from sample matrices based on the 
different distribution in the water-immiscible organic phase and aqueous phase. It is 
successful in giving excellent sample cleanup. But the disadvantages for LLE include the 
relatively large sample and solvent consumption, possible formation of emulsion, and 
unsuitability for hydrophilic compounds.  Based on the conventional LLE, the salting-
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out-assisted-LLE is developed as a more convenient alternative by adding concentrated 
ammonium salt solution into a mixture of biological sample and water-miscible solvents.  
In this way, high-throughput LLE can be applied through the automation of the handling 
process in 96-well plate.  
 
The separation process of SPE method prior to sample analysis is similar to LC 
separation. The analyte is isolated relying on its affinity difference with the liquid sample 
solution and the solid SPE sorbents. Depending on the interaction of analyte and the 
selected solid phase, the SPE sorbents vary from polymer based ion-exchange materials 
to silica based materials. Typical SPE procedures start with the conditioning of the 
cartridge by a solvent or water (Fig. 1.5). Then the sample is added onto the cartridge and 
the analyte interacting with the sorbent is retained. While the interferences are removed 
after rinsing the cartridge with buffer or solvent, the analyte can be eluted with an organic 
solvent and further concentrated by evaporation and re-constitution.  
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Figure 1.5, Illustration of four steps when performing SPE  
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Conventional SPE is performed on single cartridge, with the limitation for large volume 
of eluates and subsequent time-consuming evaporation process. The on-line SPE mode 
can be fully automated for directing injection of sample without any pretreatment. This 
advantage promotes the use of on-line SPE and 96-well plate, together with a column-
switching system in high-throughput analysis to facilitate the extraction speed. The 
runtime for high-throughput analysis using SPE-LC-MS was reported to be within 5 min 
for many applications [15-17]. 
 
1.2.2.3. Matrix effect 
 
Matrix effect is one of the major issues encountered during LC-MS method development 
and validation [18]. The phenomenon of matrix effect is observed when the ionization of 
analyte is suppressed or enhanced by the undetected co-eluting components from the 
biological matrix. The adverse results of matrix effect are reduced sensitivity for the 
detection and deteriorated precision and accuracy of the assay. According to the FDA 
guideline, it is required to assess the matrix effect when developing a reliable 
bioanalytical method. 
 
In order to quantitatively determine the absolute matrix effect, an useful strategy was 
proposed by Matuszewski et al. [19]. The matrix effect is evaluated by comparing the 
signal response of analyte obtained from a neat solution with that from a post-extraction 
solution. In this way, two sets of samples are examined: one set is prepared by spiking 
standard analyte in neat solution and the other set is prepared by spiking standard analyte 
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at the same concentration in the extracted solution of blank biological sample, which is 
termed as post-extraction solution. The difference of response from these two sets 
determines whether signal is suppressed or enhanced. More importantly, the relative 
matrix effect should be evaluated by comparing the response of analyte in post-extraction 
solution from different blank matrix sources. 
 
The post-column infusion of analyte is usually helpful to locate the co-eluting substances 
causing suppression in an LC run. A mixing tee is setup after the column elution and 
prior to MS ionization interface (Fig. 1.6). The post-extraction solution of a blank 
biological matrix is injected into the LC system, and then eluted by the mobile phase 
from the column. At the mixing tee, the matrix eluents mix with the analyte, which is 
infused constantly through an individual syringe pump. The MS monitors the signal 
change after the injection of post-extraction solution. The signal response of analyte 
should be expected to be steady in the absence of suppressing impurities. When the ion 
suppression or enhancement of analyte is present, the signal response will drop or 
increase at certain time points when interferences are eluted out, which can be easily 
observed on the chromatogram. In this way, the elution time of the ionization 
interferences and the extent of suppression or enhancement effect can be assessed 
through several continuous runs. The subsequent experimental design of analyte elution 
should avoid the co-elution with interferences. 
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Figure 1.6, The post-column infusion experiment used for the assessment of matrix 
effect 
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Matrix suppression is induced by different reasons ranged from endogenous compounds 
from inadequate sample clean-up, ion-suppression mobile phase additives, choice of 
ionization method, to sample storage conditions. One of the most extensively used and 
efficient method to solve matrix effect issue is the utility of stable isotope labeled (SIL) 
internal standard. Since the SIL internal standard has very similar chemical structure and 
properties compared to the analyte, the ionization suppression or enhancement effect on 
both compounds is expected to be the same level. However, the SIL internal standard is 
costly and sometime hard to obtain. It is also problematic for tackling the “cross talk” 
problem if the purity of SIL internal standard is not adequate.  
 
The matrix effect can also be minimized by improving the sample extraction method to 
remove the interferences. The endogenous compounds in biological samples have 
different polarity and thus are difficult to be completely removed by sample extraction 
methods. However, choosing the optimal sample preparation to reduce the amount of 
interferences is an efficient approach to ensure success in method development. Little et 
al. identified the phospholipids as a major contributor of matrix effect in blood and 
plasma by MS/MS using different extraction methods [20]. Their results suggested that 
the glycerophosphocholines caused matrix effect in both positive and negative 
ionization, with larger effect for isocratic elution than gradient elution. As the effect of  
different sample pretreatment methods on matrix effect, it is reported that LLE had 
lower signal suppression compared to SPE, followed by the PPT extract, which usually 
contains the most endogenous residues (Fig. 1.7) [21].  
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Figure 1.7, Infusion chromatograms (2.5 min) showing the ability of different 
sample preparation methods to remove endogenous sample components [21]. Panels 
(a) through (f) show the SRM XIC of a post-column infusion of phenacetin showing 
the effect of an on-column injection of 10 mL of a blank plasma sample prepared by 
each of the tested sample preparation methods. (a) Plasma protein precipitation 
blank. (b) Plasma Oasis SPE blank. (c) Plasma MTBE liquid-liquid extraction blank. 
(d) Plasma Empore C2 disk SPE blank. (e) Plasma Empore C8 disk SPE blank. (f) 
Plasma Empore C18 disk SPE blank.  
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Alternatively, adjusting the chromatographic conditions is another approach to reduce or 
eliminate the matrix suppression. In the RP-LC separation, the suppression effect is often 
found in an early time of isocratic elution program and at the end of gradient elution 
during the post-column infusion. Therefore, it is wise to alter the elution of target analyte 
at other regions of the chromatogram where the matrix effect is the lowest. Some mobile 
phase additives such as triethylamine (TEA) and TFA can also induce matrix effect in 
LC-MS analysis. The strong ion-pairing ability of these additives helps trap very polar 
compounds in the column and reduce peak tailing, but it also masks the detection by 
neutralizing the positive charge of analyte. The use of ammonium salts as a substitution 
or the choice of other columns with different retention mechanism can relieve this 
problem.  
 
In bioanalytical method development, matrix effect is more frequently reported in ESI 
interface MS than APCI since the ionization mechanisms are different in these two 
sources. In ESI, the analyte is charged when traveling in the electrical probe, then 
nebulized to small droplets, and at last evaporated in the gas phase. When the interfering 
compounds compete with the analyte for the surface charge, the charge transfer occurs if 
the interferences have higher proton affinity, causing the lost of charge for the analyte 
and the decrease of MS intensity. Compared to ESI, the APCI of analyte in liquid 
undergoes opposite sequence for evaporation and ionization. The evaporation of liquid 
solvent takes place in the capillary before the ionization by charge transfer from the 
corona probe. 
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In addition to the endogenous compounds causing matrix effect problems, other often 
neglected sources from the dosing vehicles and blood anticoagulant can also result in ion 
suppression. Dosing vehicles including propylene glycol, Tween 80, and hydroxypropyl-
β-cyclodextrin are often used in the pre-clinical PK studies. Undetected matrix effect in 
the post-dose samples would give underestimated drug concentration and generate PK 
results with large errors. It also has been suggested that heparin should be avoided for 
separating plasma from blood during sample handling [22]. Sodium EDTA usually is 
preferred for anticoagulation in the PK and toxicokinetics studies for the prevention of 
matrix effect. 
 
1.2.3. Mass spectrometric analysis for proteins 
 
In the scientific process of biomarker discovery and evaluation, a lot of assays including 
ELISA, functional assays, flow cytometry, immunohistochemistry, and MS have been 
developed for biomarker analysis [23]. The interfacing of LC with MS, with the ability in 
qualification and quantitation, is the principal technique to define proteomes. Direct 
sequencing can be obtained by generating protein or peptide signature spectra and then 
imputing the spectra fingerprint into proteomics database.  
 
1.2.3.1. Identification of differentially expressed protein candidates 
 
Body fluids are the major sources to characterize proteome. However, the analysis of 
proteins in human blood or urine presents a lot of challenges owing to the dynamic range 
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of protein concentration and complexity of sample components. The pre-fractionation of 
proteins is necessary to deplete the high-abundance proteins before MS analysis. With 
this purpose, different separation methods have been well developed prior to protein 
characterization.  
 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) tandem with MS 
analysis is the first tool used to separate and identify differentiated proteins [24]. 2D-
PAGE separates thousands of proteins by two steps. Firstly, samples are isolated by their 
different isoelectric points and by their molecular sizes. In this step, the protein pattern 
can be visualized by staining the gel. Secondly, the spots representing differentially 
expressed proteins are excised and digested into peptides by enzymes prior to MS 
analysis. However, when both abundant and less abundant proteins are presented on the 
same gel, it is necessary to determine the relative intensity of protein spots. Matrix-
assisted desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) is 
commonly applied in spot identification to generate protein or peptide fingerprint. The 
MALDI-TOF MS analysis takes advantages in unlimited mass range and fast analysis 
speed. Bioinformatics can subsequently be utilized to search the proteomic database to 
identity the targeted proteins or directly analyze the results for discriminating protein 
patterns from control to patient samples.  
 
Although 2D-PAGE with MALDI-TOF MS analysis is a simple and widespread tool for 
the analysis of complex protein mixtures, it have several limitations such as the relative 
low resolution of 2D-PAGE separation and the reproducibility of detection, and it is 
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restricted to protein less than 20k Da [25]. Micro-scale or nano-scale chromatographic 
separation enhances the speed and efficiency comparing to conventional 2D-PAGE, 
facilitating the incorporation of high resolution LC in tandem MS as the primary protein 
identification platform.  
 
The LC-MS/MS protein analysis can be performed on various mass spectrometers, such 
as quadurpole and linear ion traps, Orbitrap, and quadrupole-TOF. The bottom-up 
method for protein primary sequence determination involves the enzymatic digestion of 
protein into small peptides (Fig. 1.8). Retaining the digested peptide in acidic condition, 
the C18 reverse-phase microcapillary or nano-LC columns are the most commonly used 
ones to fractionate peptides with high resolution. 
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Figure 1.8, Bottom-up proteomics analysis using LC-MS/MS. Trypsin digestion is the 
first step for the analysis of a complex protein mixture. Afterward, the sample 
containing tryptic peptide is injected into the HPLC column of the LC-MS/MS system. 
The mass spectrometer generates parent (MS
1
) spectrum and fragmentation (MS
2
) 
spectrum created by CID. The computer will use the MS2 spectrum together with MS1 
spectrum to compare the database containing theoretical peptide spectra to identify the 
protein of origin. 
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The gradient program of the LC system helps the elution of the peptides. When delivered 
to the mass spectrometer in acidic environment, the peptides are converted into cationic 
form with single or multiple charges [26]. The first stage is to produce MS
1
 spectra for 
the m/z of various peptides. To generate more information for peptide identification, the 
fragments of selected peptide ions (precursor ions) are initiated. To produce fragment 
ions, tandem mass spectrometric analysis (MS/MS) uses collision-induced dissociation 
(CID) to generate MS
2
 data for peptide sequence information. By searching the protein 
database with the acquired MS/MS spectra, the software program can identify protein 
with matching peptide mass fingerprinting. Clearly, the higher mass accuracy obtained 
from precursor ions and product ions, the more confidence for protein identification.  
 
1.2.3.2. Quantitative protein analysis 
 
With the speed-up of generating biomarkers, the center of proteomics has shifted from 
biomarker discovery to biomarker evaluation and quantification. It is necessary to 
compare the amount of differentially expressed proteins among healthy and disease status. 
Therefore, the development of accurate methods to quantify biomarkers of interest is a 
reliable theme for biomarker evaluation. Currently, the established techniques for protein 
and peptides quantification include two general strategies: 1) non-labeling methods by 
correlating MS signal with relative protein quantity and 2) the use of stable isotope 
incorporation prior to MS analysis.  
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In non-labeling quantification, the quantitative information for specific peptide is 
derived from according ion intensity or peak areas in complex peptides mixture. The 
accurate quantification needs a careful calibration of instrument system and 
normalization of MS spectra. For LC-MS/MS quantification, peptide ion intensity 
counting of MS mode and spectral counting in MS/MS mode are extensively used for 
ion detection. With respect to peptide ion counting, the number and intensity of 
precursor ion or peak area at selected m/z can be obtained. The spectral counting 
approach refers to the number of fragment ions generated from selected peptide. The 
peptide levels are yielded by comparing referring the abundance of peptide between 
samples in two or more separate LC-MS/MS runs. Label-free approach for quantitative 
proteomics is preferable due to its low cost and no limitation for sample numbers [27].  
 
However, there are still controversies for the reliability of label-free quantitative 
analysis. The accurate quantification of this approach requires the minimization for 
variations between different runs, high resolution for the chromatography to finding 
correlated peptide, and high MS accuracy to prevent interfering signals with similar m/z. 
It also assumes that the linearity of response is the same for every peptide, but in fact 
the spectrum count response varies from different peptides. Because of the dynamic 
range of peptides in a sample, the existence of high abundance peptide in the complex 
mixture will affect the accuracy of low abundance peptide quantization.  
 
The major stable isotope labeling methods include using isotope coded affinity tags 
(ICAT) and isobaric tags for relative and absolute quantification (iTRAQ) [28].  The 
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basic principle of ICAT relies on a special affinity tag to react with cysteine residues 
and allows differentially labeled samples to be resolved with MS analysis. Two 
different tags, which are identical except for one has hydrogen and the other one has 
deuterium atoms in the linker, react with samples before protein digestion [28]. Their 
mass difference allows the relative quantitative measurement by MS. The 
disadvantages of ICAT are its limitation for proteins containing cysteine residues only 
and high cost due to the isotope reagent.  
 
The iTRAQ approach allows multiplexed quantification by targeting all free amines at 
N terminus of all peptides and the epsilon-amino group of lysine residues. This 
technique enables the analysis of up to 8 samples in one run. The iTRAQ tags contain 
reporter group with mass from 114 to 117 Da, balance group from 28 to 31Da, and a 
protein-reactive group. During each MS scan, each labeled peptide displays the same 
mass to charge ratio. However, the dissociation of the reporter groups displays different 
m/z after the fragmentation under MS/MS mode. Signals from peptides after isobaric 
labeling are acquired for both MS and MS/MS scanning mode, thus improving the 
sensitivity and specificity of detection [29].  This property has great potential in the 
quantification of low abundance proteins. iTRAQ coupled with LC-MS/MS has been 
used as in the serum biomarker in several studies and it shows promise in determining 
differential expression profiles for cancer diagnosis, prognosis or monitoring of 
treatment [30]. 
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When the quantitative information is derived for cataloging the protein files in a sample, 
the biomarker development requires careful follow-up validation, which includes the 
application of targeted proteomics methods. Targeted proteomics focused on individual 
proteins or a panel of proteins. When the use of isotope labeled methods only can provide 
relative quantitative information, the use of a standardized reference in the sample 
provides the absolute quantification information (AQUA).  It is performed by spiking an 
isotopically-labeled internal standard into a biological sample prior to MS analysis. The 
ratio of labeled to unlabeled peptide determined by MS analysis can be calculated and the 
abundance of specific protein can be derived. Combining AQUA with MRM method in 
MS analysis, the specificity and accuracy can be improved for absolute quantification. 
MRM involves the selection of parent ions and then monitoring the fragmentation ions 
from the selected parent ions, thus enabling this technique highly specific and sensitive.  
Because the MRM detection limit allows at low as ng/ml level, this method offers the 
most promise for biomarker validation. 
 
To develop proteomics biomarkers with high specificity and sensitivity for clinical 
application, several phases including biomarker discovery, evaluation, determination of 
biological relevance, and development of clinical assay are need to follow. Huge 
challenges were presented such the complexity, variation and dynamic range of proteins 
in biological samples. The new MS technologies play the most critical role in the 
improvement of resolution and sensitivity, bringing promises for more clinical successes. 
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1.2.4. PCR based methods for methylation profiling 
 
DNA methylation is the most studied epigenetic changes related to normal biological 
processes and many diseases, especially in cancer development. This covalent 
modification of cytosine mostly happens at CpG dinucleotides rich sites, which are 
associated with gene promoters. While the methylation in normal cells is regulated by the 
DNA methyltransferases in a steady status for a stable genome, the aberrant gene 
methylation represses the transcription of downstream genes. In the process of 
tumorigenesis, a large number of tumor suppressor genes were found to be 
hypermethylated in the promoter regions [31]. Based on these findings, the investigation 
on DNA methylation has become one of the most popular areas in molecular oncology. 
Technologies for the genomic DNA methylation profiling are designed with enormous 
improvements with regarding to sensitivity, the elimination false-positive results, and 
sample throughput.  
 
In currently used methodologies for methylation profiling, bisulfite conversion based 
method is the fundamental one to investigate the gene-specific methylation. With 
standard sequencing method, the similar base-pairing sequence of methylated and 
unmethylated cytosine cannot be distinguished. Sodium bisulfite treatment with genomic 
DNA can solve this problem by chemical reaction. Under certain conditions, sodium 
bisulfite specifically deaminates unmethylated cytosine to uracil but leaves the 
methylated cytosine unchanged (Fig. 1.9.). The uracil is replaced with thymine in the 
followed PCR amplification after bisulfite conversion. After this reaction, standard 
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methods such as sequencing, pyrosequencing, PCR, or mass spectrometry can be used to 
analyze the bisulfite-converted DNA product [32-34]. 
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Figure 1.9, Strategy to distinguish unmethylated cytosine and methylated 
cytosine by bisulfite reaction  
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However, bisulfite treatment may give inaccurate results when the incomplete conversion 
of unmethylated cytosine is misinterpreted as methylated cytosine. It is critical to ensure 
the reaction is complete for unmethylated DNA by spiking known unmethylated DNA 
with the reaction as control. Another issue is the partial degradation as a result of DNA 
depurinization at acidic pH, which limits the sensitivity of the PCR reaction [35]. This 
problem can be overcame by adjusting the proper bisulfite reaction conditions of pH, 
temperature and the time of reaction [35].  
 
 Direct sequencing of bisulfite treated DNA allows the detection of methylation for each 
CpG dinuclotide within the analyzed area, thus is considered as the golden standard for 
methylation profiling. Nevertheless, the cost and labor intenseness of this approach is 
extremely high for large-scale sample analysis.  
 
Alternatively, the differences between unmethylated and methylated DNA sequence can 
be characterized by melting curve analysis. Unmethylated and methylated DNA has 
different GC content after bisulfite conversion, presenting varied resistant levels to 
melting. To detect the signal of PCR product, fluorescence dyes are used for specific 
binding with double-stranded DNA (ds DNA). The fluorescence signal is monitored as 
the temperature increases, producing a melting curve to depict the relationship between 
fluorescence intensity with the increase of temperature. The characteristics of PCR 
product is indicated by the fluorescence peak with a certain melting temperature on the 
derivative melting curve. The fully methylated PCR product and fully unmethylated 
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DNA shows distinct melting peaks, while a mixture of both may show a complex pattern 
with both melting peak characters [36] (Fig. 1.10).  
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Figure 1.10, Melting curve analysis on fully methylated, fully unmethylated, and 
mixtures of both PCR products for methylation detection [34]. 
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These sequencing and MCA methods such as combined bisulfite restriction analysis 
(COBRA), melting curve analysis methods including methylation-sensitive single-
nucleotide primer extension (MS-Snupe), and methylation-sensitive melting curve 
analysis (MS-MCA) all reply on the PCR amplification prior to methylation detection. 
Methylation-independent PCR primers utilized in these methods allow proportional 
amplification of methylated and unmethylated templates. However, the templates of 
methylated DNA have higher GC content than unmethylated templates, leading to 
different amplification efficiencies and PCR bias for unmethylated product. Although 
many attempts are reported to overcome this problem such as increasing the annealing 
temperature during amplification and proper primer design [37], the sensitivity of these 
methods remains to be improved.  
 
The development of methylation-specific PCR (MSP) in the mid-90s permits the simple 
and fast analysis of the DNA methylation status after bisulfite conversion. MSP method 
is highly sensitive and specific with designed PCR primer for the amplification of 
methylated sequence only. It was reported that MSP was able to detect 0.1% methylated 
template in a pool of unmethylated DNA [38]. MSP is also related with high false-
positive rates caused by the incomplete bisulfite conversion and possible contamination 
during analysis, which can be alleviated by increasing melting temperature and more 
stringent amplification conditions.  
 
The development of quantitative MSP (qMSP) resolves the limitation of MSP based on 
real-time PCR (RT-PCR). The amount of initial DNA product can be determined with 
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high precision and a wide range. In addition to unknown DNA products, standard 
methylated DNA after bisulfite treatment is serially diluted and amplified for standard 
curves in separated reactions. Since the quantitative results are relative to the standards, 
the absolute quantity of DNA only can be obtained when the absolute copies of the 
standards are known. 
 
As an alternative mechanism for cancer development, aberrant gene methylation has been 
found in the patterns of hypomethylation for global genome change and 
hypermethylation for specific tumor suppressor genes. The DNA methylation profiling 
holds promises for the biomarker discovery of cancers and other diseases for early 
detection. Nevertheless, these potential biomarkers are relative low abundant in biofluids 
or tissues, requiring the developed detection method for gene methylation to be highly 
sensitive and specific for potential clinical applications. A large number of target genes 
have been identified for colorectal cancer, breast cancer, and hepatocellular carcinoma. 
Moreover, the DNA methylation targets are more frequently to be observed as a panel of 
multiple genes rather than a single gene, suggesting a direction for improving the 
specificity of cancer screening. 
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CHAPTER II  
 
 
QUANTITATIVE ANALYSIS OF BILE ACIDS FOR INFLAMMATORY 
BOWEL DISEASES 
 
 
2.1. Introduction  
 
2.1.1. Bile acids 
 
Bile acids are produced in the hepatocytes through the oxidation of cholesterol. They are 
composed of a steroid structure with side chain terminating in a carboxylic acid and 
hydroxyl groups (Fig. 2.1). After conjugating with taurine or glycine in the liver, bile 
acids are excreted into gallbladder, released into intestinal tract, reabsorbed in the 
terminal ileum, and then back to enterohepatic circulation, leaving a small part entering 
into the colon [1,2] (Fig. 2.2). In the terminal ileum, cecum and colon, primary bile acids 
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including cholic acid (CA) and chenodeoxycholic acid (CDCA) are metabolized by 
bacterial flora through two major reactions: one is deconjugation to produce free bile 
acids and taurine or glycine from conjugated bile acids; and the second one is 
dehydroxylation to form secondary bile acids deoxycholic acid (DCA), ursodeoxycholic 
acid (UDCA) and lithocholic acid (LCA) [3]. The numerous metabolic conversions of 
bile acids bring the complexicity of bile acids composition in biological fluids. 
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Figure 2.1, Chemical structures of bile acids (a) and internal standard NPA (b) 
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Figure 2.2, Bile acids metabolism 
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Under the physiological conditions, bile acids are only present at low concentrations in 
the peripheral circulation due to the hepatic extraction and intestinal absorption. The 
excretion of bile acids from feces stands for 10% -15% of total daily bile acids 
production in human. In hepatobiliary and intestinal diseases, the cholesterol metabolism 
is disturbed, affecting the synthesis of bile acids and conversion of bile acids in different 
biological fluid (serum, bile, urine, and feces). The bile acids quantitative and qualitative 
changes in feces provide possible correlation with the development and prevention of 
liver diseases and intestinal diseases. 
 
2.1.2. Inflammatory Bowel Diseases (IBD) 
 
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis 
(UC), significantly affects the quality of life of many patients in western world [4]. A 
standard surgical procedure called ileal pouch anal anastomosis (IPAA) is usually used 
for the treatment of UC. However, patients often develop inflammatory complications of 
ileal pouch after the surgery, among which, pouchitis is the most common and non-
specific one [5](Fig. 2.3). The non-specific symptoms of pouchitis bring great challenges 
in the diseases diagnosis and management. 
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Figure 2.3, IBD and its treatment by IPAA surgery 
(http://www.adam.com/) 
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The pathophysiology of pouchitis is not completely understood yet, while one of the 
important factors could be the bacterial overgrowth in the ileal pouch reservoir [6]. In 
hepatobiliary and intestinal disorders, the abnormal cholesterol metabolism affects the 
bile acids synthesis, enterohepatic circulation, and biotransformation process, thus 
changing its composition in biofluids. Kruis et al. and Natori et al. reported that altered 
bacterial conversion of primary to secondary bile acids was related to abnormal intestinal 
microflora in UC patients [7, 8]. Therefore, monitoring the change of bile acids profile 
through bile acids quantification may serve as a useful diagnostic test for the ileal pouch 
diseases developed for the treatment of IBD.  
 
2.2. Development of a quantitative bioanalytical method for fecal bile acids 
 
2.2.1. Challenges in method development 
 
Due to the complex composition and minor difference between bile acids components, 
the quantification of fecal bile acids is challenging. Most of the current methods use gas 
chromatography–mass spectrometry (GC-MS) for the analysis of bile acids in feces [9, 
10]. Because of the comprehensive bile acids analysis requires the separation of free bile 
acids and the conjugated ones, the major disadvantage of the GC-MS approach is the 
tedious and time-consuming derivatization and pre-fractionation steps prior to analysis.  
 
LC-ESI-MS is a powerful technique for the simultaneous analysis of multiple bile acids 
in biological materials including plasma, serum and urine with high specificity and 
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selectivity [11,12]. One of the challenges is the separation for the dihydroxy C24 bile 
acids presenting isomeric structures. The detection of bile acids is often operated in SIM 
mode for free bile acids and MRM mode for glycine and taurine conjugates. There was 
also a report that utilized LC-ESI-MS to analyze fecal bile acids, but its accuracy and 
precision were not reported [13]. 
 
Matrix effect is another common problem associated with analysis of a complex 
biological sample with mass spectrometry. This phenomenon in ESI was observed when 
the target analyte is co-eluted with other bio-fluid components [14]. The endogenous 
phospholipids, proteins and fatty acids in the biological samples are the main source of 
the matrix effect. The ionization of analyte in mass spectrometry can vary greatly, which 
in turn significantly affects accuracy and precision of measurements [15,16]. The affected 
signal intensity can be explained as the competition among ions for the limited droplet 
surface charge [17]. For example, Scherer et al. reported the matrix effect during the 
analysis of bile acids in serum [18]. We also encountered serious matrix suppression 
problem during the course of our own analysis of fecal materials. 
 
In this work, we have developed a simple and effective method termed as standard 
addition with internal standard (SA-IS) method to overcome the large quantitative errors 
brought by matrix effect. Combining standard addition with internal standard, the SA-IS 
method takes advantages of both, which compensates matrix effect and variations in 
sample preparation and MS detection. In this study, we studied seven bile acids CA, 
CDCA, DCA, UDCA, LCA, taurochenodeoxycholic acid (TCDCA), and 
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glycochenodeoxycholic acid (GCDCA) using the SA-IS method along with a simple 
sample pretreatment procedure. The sensitivity, accuracy, reproducibility of this method 
were evaluated and improved to the acceptable range for the quantitative determination of 
bile acids in fecal materials such as pouch aspiration. We expect that the SA-IS approach 
developed in this work can be a general method for the quantitative analysis of other 
complex samples by LC-ESI-MS, in which the matrix effect exists. 
 
2.2.2. Chemicals and methods 
 
2.2.2.1. Chemicals 
 
CA, CDCA, DCA, UDCA, LCA, GCDCA, TCDCA, N-1-napthylphthalamic acid (NPA), 
ammonium hydroxide and ammonium acetate were purchased from Sigma-Aldrich 
Chemical (St Louis, MO, USA). HPLC-grade methanol and acetonitrile were also 
purchased from Sigma-Aldrich. Deionized water was generated by a Millipore water 
purification system (Billerica, MA, USA). Syringes and syringe filters were obtained 
from VWR international (Wester Chester, PA, USA). 
 
2.2.2.2. Sample collection 
 
The pouch aspiration used in this study is one kind of homogenous fecal materials. 
Diagnostic or surveillance pouch endoscopies, a subspecialty of the Pouthitis Clinic at 
Cleveland Clinic (Cleveland, OH, USA), were performed as a part of routine clinical care. 
 59 
The project was approved by Institutional Review Board at Cleveland Clinic. Informed 
consent was obtained from all patients. Before pouch endoscopy, each enrolled patient 
was given one Fleets®enema, and in 5–10 min the patient went to empty the pouch. 
Pouch aspiration samples were collected during pouch endoscopy and stored at −20°C. 
 
2.2.2.3. Instrumentation and LC-MS conditions 
 
The LC-MS system consisted of an Agilent 1100 series HPLC (Santa Clara, CA, USA) 
and a Waters Micromass Quattro II triple quadrupole mass spectrometer (Manchester, 
UK). A Luna C18 column (150 mm, 2mm i.d., 5 μm) with a guard column (40 mm, 2mm 
i.d.) from Phenomenex (Torrance, CA, USA) was used for the chromatographic 
separation. The mobile phase was a gradient mixture of 10 mM ammonium acetate–
ammonium hydroxide buffer at pH 8.0 (A) and 10mM ammonium acetate in acetonitrile-
methanol 3:1 (B). The gradient elution program is illustrated in Figure 2.4. The HPLC 
column was first equilibrated with an initial mobile phase of 30% B. The mobile phase 
was then increased to 65% B within 6 min and increased to 72% B from 6.1 to 14 min. 
Afterward the mobile phase was changed to 90% B in 1 min and maintained for 5 min. At 
20 min, the proportion was adjusted back to the initial ratio condition of 30% B and 
maintained for 10 min to re-equilibrate the column. During the entire analysis the flow 
rate was 200 μL/min. The injection volume was 10 μL and the total run time was 30 min 
for each sample including the re-equilibration. 
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Figure 2.4, The gradient elution for the separation of bile acids 
 
 61 
Negative ESI mode was adopted for the mass spectrometer operation. A small portion of 
flow (50 μL/min) was introduced to the mass spectrometer with a post-column split ratio 
of 1:4. Direct infusion of each bile acid at 1 μmol/L and the internal standard (IS) at 10 
μmol/L was used to fine tune the mass spectrometry conditions. The ion source 
temperature was maintained at 95°C and the capillary voltage was set at 3.0 kV. Nitrogen 
nebulization and drying gas were held at 12 and 300 L/h, respectively. Cone voltage was 
at 50 V. Detection of bile acids was performed using selective-ion monitoring (SIM) 
mode. The deprotonated molecules of the free and conjugated bile acids were recorded at 
m/z 375.2 (LCA), 391.3 (UDCA, CDCA and DCA), 407 (CA), 448 (GCDCA), and 498 
(TCDCA). Micromass Masslynx (Version 3.3) was utilized for system operation, data 
acquisition, and data processing. 
 
2.2.2.4. Stock and working solutions 
 
Stock solutions of each bile acid and IS were prepared at a concentration of 14 mmol/L 
by carefully weighting each compound and dissolving them in methanol. Stock solutions 
were stored under −20°C. The dilution buffer, 70% mobile phase B, was used for the 
preparation of bile acid working solutions at 20, 40, 80, 100, 200, 400, 800, 1000, 1600, 
and 2000 μmol/L per compound. The one with the highest concentration was prepared by 
mixing equal volumes of seven bile acid stock solutions together; other lower 
concentrations were obtained by serial dilution. The IS working solution at 4000 μmol/L 
was prepared by diluting the IS stock solution.  
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2.2.2.5. Pouch aspiration calibrators and Quality Control (QC) samples 
 
The collected pouch aspiration samples were homogenous and thawed before use. The 
blank pouch aspiration lots, which had no detectable ion signals for given bile acids, were 
obtained from different IBD patients. The calibrators and QC samples used different two 
lots of blank pouch aspiration. Bile acids calibrators of 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 5 
μmol/L were obtained by spiking 15 μL bile acid working solutions of 20, 40, 100, 200, 
400, 1000 and 2000 μmol/L into 30 μL blank pouch aspiration, respectively. In the same 
way, bile acids QC samples of 0.2, 2 and 4 μmol/L were prepared by spiking 15 μL bile 
acids working solutions of 80, 800 and 1600 μmol/L into 30 μL blank pouch aspiration, 
accordingly. There is a 400 times’ concentration difference between the stock solution 
and wanted final concentration of bile acids considering the sample treatment procedures 
described in the following section. 
 
2.2.2.6. Sample treatment of calibrators and QC samples for internal calibration 
 
After thawing the pouch aspiration calibrators and QC samples to room temperature from 
−20°C, they were homogenized using a mixer. Prior to sample extraction, each aliquot of 
45 μL calibrators and QC samples was mixed with 15 μL IS working solution for the 
internal standard calibration. For the sample preparation, each of the mixed samples was 
added with ethanol to obtain a total volume of 600 μL. The whole mixture was sonicated 
by an ultrasonic bath for 15 min. After a centrifugation at 10,000 rpm for 5 min, 100 μL 
supernatant was removed and diluted 10 times using the dilution buffer. The solution was 
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then filtered using a syringe filter with a pore size of 0.45 μm. Finally, the filtrated 
solution was injected into LC-MS system for analysis. 
 
2.2.2.7. Sample treatment of QC and patient samples for SA-IS 
 
Two portions of QC sample and patient sample were needed for each analysis when 
applying the SA-IS method. The QC sample analysis required each portion as 45 μL and 
the patient samples analysis required each portion as 30 μL. Before the sample extraction, 
one portion was spiked with 15 μL IS working solution, and the other was spiked with 
both the 15 μL IS working solution and 15 μL bile acid working solution at 800 μmol/L. 
The following sample preparation procedure was the same as that described in the section 
“Sample Pretreatment of Calibrators and QC Samples for Internal Calibration”. 
 
2.2.2.8. Matrix effect and recovery 
 
For the evaluation of matrix effect in pouch aspiration, the chromatographic peak area 
ratios of bile acids to IS in matrix-contained solution were compared with those for the 
non-matrix contained solution. The matrix-contained samples were prepared as follows: a 
30 μL blank pouch aspiration sample was extracted, diluted, and filtrated by the 
procedure described above. Further, bile acids and IS working solution were spiked into 
the post-extraction (SPE) solution. The non-matrix contained solutions of bile acids were 
the reference samples and were prepared by diluting bile acids work solution using 
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dilution buffer. The matrix effect was determined in two different lots of blank pouch 
aspiration under three concentration levels: 0.2, 2 and 4 μmol/L. 
 
For the determination of extraction recovery, the chromatographic peak area ratio of bile 
acids to IS in the spiking-before-extraction (SBE) solution was compared with that in the 
SPE solution. The preparation method of bile acids and IS in the SBE solution was the 
same as preparation of QC standards. The recovery was also determined under three 
concentration levels: 0.2, 2 and 4 μmol/L. 
 
2.2.2.9. Method validation 
 
After the development of this SA-IS method, we validated it by assessing the linearity, 
limit of detection (LOD), lower limit of quantification (LLOQ), and the intra- and inter-
assay precision and accuracy. Bile acids calibration curves were constructed over the 
range of 0.05-5 μmol/L. The peak area ratios of bile acids to the IS in the pouch 
aspiration sample (y) were regressed against the concentration of spiked standard bile 
acids (x).  
 
The LOD and LLOQ samples were prepared by spiking 15 μL bile acid working 
solutions with 30 μL blank pouch aspiration. The LOD for bile acids in pouch aspiration 
was determined when the signal-to-baseline noise ratio was above 3. The LLOQ was the 
lowest concentration of bile acids in pouch aspiration that could be determined within a 
precision and an accuracy of 20%.  
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Intra-assay precision and accuracy were determined in five replicates of QC samples at 
0.2, 2 and 4 μmol/L prepared in the same run. Inter-assay precision and accuracy were 
measured in three different runs. The precision was expressed in terms of percentage 
coefficient of variation (CV%) and accuracy was expressed in terms of percent relative 
errors (RE%). 
 
2.2.2.10. Method application 
 
To test the feasibility of this SA-IS method in fecal material analysis, we determined the 
bile acids profiles for a preliminary clinical application. The clinical pouch aspiration 
samples were collected from the patients diagnosed as having pouchitis and normal 
pouch after IPAA surgery. 
 
2.2.3. Results and discussion 
 
2.2.3.1. Separation of bile acids 
 
A broad range of the bile acids physicochemical properties including PKa and 
hydrophobicity, along with the minor difference between some isomeric bile acids, bring 
great challenges in bile acids separation. The free and conjugated bile acids have different 
PKa range at 3.9 ± 0.1 and 5.0 ± 0.1, respectively [19].  The Log D values of bile acids 
distribute from 0 to 4 for all bile acids [20]. Among these seven compounds, UDCA and 
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CA are the most hydrophilic bile acids, while DCA and LCA are the most hydrophobic 
ones.  
 
The separation of bile acids CDCA, UDCA, DCA, LCA, CA, TCDCA, and GCDCA was 
achieved with a Luna C18 column from Phenomenex. The isomeric bile acids CDCA and 
DCA were the most difficult to separate. The mobile phase was optimized to achieve 
complete separation of these two isomers by using different ratio of methanol, acetonitrile, 
and mobile phase additives. The addition of methanol to the organic mobile phase could 
sharpen bile acids peaks [21]. The retention times and sensitivity of bile acids were 
improved by adding ammonium salts into the mobile phase and adjusting the pH by 
ammonium hydroxide at pH 8.0. When the mobile phase is basic, the variation of log P 
on the change of pH is the lowest, and consequently the deprotonation of bile acids is 
promoted. Three different concentrations of ammonium acetate: 2, 10, and 20 mM were 
tested in the mobile phase. We found that 10 mM ammonium acetate yielded the highest 
ionization intensity and best separation. With this optimized mobile phase conditions, 
gradient elution was applied to separate the analytes within 20 min and to sufficiently 
isolate three isomers of UDCA, CDCA, and DCA, as well as other bile acids (Fig. 2.5). 
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Figure 2.5, Representative mass chromatograms of bile acids at 0.1 μmol/L and IS 
NPA at 10 μmol/L 
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2.2.3.2. Matrix effect 
 
The variation of analyte signal after the extraction process for the biological sample is 
often contributed by extraction recovery and matrix effect. Recovery variation is mainly 
caused by the extraction efficiency, while matrix effect is introduced by co-eluting 
interference existing in the extracted solution. When the matrix interference shows higher 
proton affinity than targeted analyte, proton is transferred from the ionized analyte to the 
interference, causing the lost ion intensity of partial analyte [14]. It has been reported that, 
when LC-MS was used to analyze biological samples such as urine and plasma, matrix 
effect often occurred and caused deterioration of the precision and accuracy of the 
analysis [22-24].  
 
The evaluation of matrix effect during LC-MS analysis usually employed the following 
methods: post-column infusion, post-extraction spike, and the comparison of standard 
calibration slopes. In this study, the post-extraction spike method and the comparison of 
standard calibration curves were employed to assess the matrix effect on bile acids in 
pouch aspiration samples. 
 
NPA was selected as IS to normalize MS signal for all bile acids because of their similar 
structures and chemical properties [25](Fig. 2.1). After the normalization of MS variation 
by the IS, the matrix effect (ME %) was measured by comparing the peak area ratios of 
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bile acids to IS spkied in post-extraction solution and with those in dilution buffer 
according to [26]: 
 
ME%  (1
R
SPE
R
DB
) 100%  
where RSPE represents the peak area ratio determined in the SPE solution of blank pouch 
aspiration and RDB represents the peak area ratio determined in the dilution buffer. The 
positive ME% indicates matrix suppression of target analytes; the negative ME% 
indicates an enhancement of ionization by sample matrix; and zero of ME% indicates no 
matrix effect is present. In addition, we compared the ME% from two different batches 
(No.398 and No. 957) of blank pouch aspiration at three concentrations: 0.2 μmol/L, 2 
μmol/L, and 4 μmol/L. 
 
In addition, three calibration curves of bile acids were established in the non-matrix 
contained solution, matrix contained solution after extracting blank plasma sample lot 1, 
and matrix contained solution after extracting blank plasma sample lot 2 for matrix effect 
evaluation also. The slopes were compared between three calibration curves. 
 
As shown in Table 2.1, the ME% in sample 398 (except for 4 μmol/L CDCA and DCA) 
ranged from 7.6 to 38%, indicating severe ion signal suppression by the pouch aspiration 
sample matrix. In sample No. 957 the ME% was even larger. These results were 
confirmed in the results from the calibration curves for bile acids in different matrix 
solutions (Fig. 2.6). The slopes of calibration curves established in non-matrix contained 
solution were higher than that in two different matrix-contained solutions. In addition, the 
level of ion suppression resulting from the pouch aspiration matrix varied greatly 
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between different samples. This is not surprising due to the highly complex nature of 
fecal materials such as pouch aspiration. 
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Bile Acids 
Concentration 
(μmol/L) 
No. 398 ME (%) 
No. 957 ME 
(%) 
CA 
0.2 30.6 45.1 
2 27.2 41.8 
4 11.8 29.9 
CDCA 
0.2 23.5 37.2 
2 23.9 37.3 
4 -1.2 18.9 
UDCA 
0.2 29.2 30.9 
2 19.2 28.3 
4 7.6 21.7 
DCA 
0.2 28.9 37.3 
2 21.1 31.7 
4 -0.3 21.6 
LCA 
0.2 37.1 47.3 
2 24.2 18.4 
4 9.7 13.3 
TCDCA 
0.2 38.0 49.3 
2 24.7 36.4 
4 8.3 26.7 
GCDCA 
0.2 35.0 38.1 
2 25.1 29.0 
4 10.7 22.4 
Table 2.1 Matrix effect determined in blank pouch aspiration 
sample No. 398 and No. 957 for bile acids at three concentrations 
(n=3) 
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Figure 2.6, Calibration curves of bile acids: CA (a), CDCA (b), UDCA (c), DCA 
(d), LCA (e), TCDCA (f), and GCDCA (g) established in different solution sets: 
non-matrix contained solution (● in orange), extracted solution of blank pouch 
aspiration lot #1 (▲in blue), and extracted solution of blank pouch aspiration lot 
# 2 (■ in purple) 
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2.2.3.3. Internal standard calibration 
 
To evaluate the availability of internal calibration for compensating matrix effect and 
determining bile acids in pouch aspiration, calibration curves were established from 
pouch aspiration calibrators. The calibrator and QC standards were prepared from two 
different batches of blank pouch aspiration samples. The QC standards of three spiked 
concentrations were measured based on the calibration curves, and the results were listed 
in Table 2.2.  
 
For most of the bile acids, the analytical accuracy with the internal standard method was 
low considering RE% ranges from -50.4% to 64.6%. These large quantitative errors 
resulted from the sample-to-sample variations in the matrix components. More 
specifically, such great errors were caused by significant differences between the level of 
matrix effect of QC standards and that of calibrators. Therefore, the internal standard 
calibration was not suitable for bile acids analysis when the matrix varied among 
samples.  
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Bile Acids 
Spiked 
Concentration 
(μmol/L) 
Accuracy 
 
RE(%)  
CA 
0.2 64.6 
2 22.7 
4 21.3 
CDCA 
0.2 -17.1 
2 -50.4 
4 -23.5 
UDCA 
0.2 39.8 
2 5.5 
4 -13.6 
DCA 
0.2 36.3 
2 7.4 
4 22 
LCA 
0.2 15.6 
2 -6.4 
4 5.2 
TCDCA 
0.2 7.4 
2 -17.3 
4 15.4 
GCDCA 
0.2 -19.5 
2 -45.3 
4 20.6 
 
Table 2.2 The accuracy results determined by internal standard method (n=5) 
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2.2.3.4. SA-IS method 
 
Several approaches were reported to reduce matrix suppression [15,16,27]. One of most 
effective approaches is the use of isotope-labeled analogues as internal standards. 
However, the presence of multiple analytes in pouch aspiration requires multiple isotope-
labeled internal standards, which are costly and difficult to obtain.  
 
Using appropriate sample extraction procedure is another approach to reduce the matrix 
effect. We tried to clean up the co-eluting substance by LLE and SPE. However, since the 
hydrophobicity of bile acids has a broad range, it is difficult to develop an LLE method 
ensuring low matrix interference and good recovery. Also the large number of lipids and 
lysophospholipids, which are similar with bile acids with regarding to structure and 
polarity, presents in pouch aspiration, causing the co-elution of bile acids and the 
interference when using SPE methods. In addition, the matrix interference, with 
significant sample-to-sample variation, could not be removed completely by the same 
sample cleanup method.  As a result, all of these purification attempts failed to reduce the 
matrix effect within 15% for all the bile acids.  
 
Standard addition was another option reported to compensate the matrix effect in LC-MS 
analysis [28,29]. It measures the concentration of analyte in an unknown sample by 
comparing the response difference between before and after the addition of a known 
amount of analyte to that of the original sample. However, standard addition alone cannot 
correct the loss of analytes associated with sample preparation. As a result, we 
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investigated the SA-IS method that combined standard addition with internal standard to 
measure the concentrations of bile acid components in pouch aspiration. The use of 
standard addition will eliminate adverse matrix effect on accuracy and precision, while 
the use of internal standard will compensate for incomplete extraction and variability in 
sample preparation and MS detection.  
 
The SA-IS method is illustrated in Fig.2.7. Cunk represents the unknown concentration of 
a bile acid in a pouch aspiration sample; CSA represents the spiked concentration of the 
bile acid in the same pouch aspiration after standard addition. The peak area ratios of the 
bile acid to IS in the original sample and in standard addition samples are Runk and RSA, 
respectively. The peak area ratios are regressed against the concentration of bile acid 
spiked in. Cunk is calculated according to: 
 
C
unk

C
SA
 R
unk
(R
SA
 R
unk
)
 
With the SA-IS method, each pouch aspiration sample was divided into two aliquots: the 
first one was spiked with only IS, and the other was spiked with the bile acids mixture 
and IS. The validation results showed that the SA-IS is effective in correcting the matrix 
effect and more accurate than internal standard method. 
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Figure 2.7, Illustration of SA-IS method 
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2.2.3.5. Method validation 
 
Linearity: Two requirements are needed when applying the SA-IS: 1) a good linear 
relationship between the analyte concentration and according signal response; 2) zero 
signal response in the absence of analyte. The linearity were studied by analyzing the 
calibrators, which were blank pouch aspiration samples spiked with bile acids and IS. 
We observed that calibration curves established by plotting the peak area ratio of analyte 
to IS vs. the concentrations of each bile acid were linear within the range of 0.05 μmol/L-
5 μmol/L with correlation coefficient of 0.9964 - 0.9999 (Table 2.3). 
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Bile Acids 
Range 
 (μmol/L) 
Calibration curve of standard bile acid in blank pouch 
aspiration sample 
slope y-intercept 
correlation 
coefficient 
CA 0.05-5 4.331 0.063 0.9998 
CDCA 0.05-5 3.543 0.016  0.9964 
UDCA 0.05-5 5.163 0.012 0.9991  
DCA 0.05-5 6.129 0.018 0.9998  
LCA 0.05-5 7.782 0.023 0.9988  
TCDCA 0.05-5 3.869 0.076 0.9999  
GCDCA 0.05-5 3.129  0.048 0.9996 
 
Table 2.3 Calibration curve results for bile acids spiked in pouch aspiration 
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Sensitivity: The sensitivity of this method was assessed in term of the limit of detection 
(LOD) and the lower limit of quantification (LLOQ). For all the bile acids, the LOD was 
1 nmol/L using a signal-to-noise ratio of 3. LOD was determined by spiking the bile acid 
standards into the blank pouch aspiration samples. The LLOQ was 0.05 μmol/L as the 
lowest end of the calibration in this study.  
 
Recovery: We performed the recovery study by determining the peak area ratios of bile 
acids to IS in SPE solution and SBE solution. The percent recovery was calculated as:  
 
 
Recovery% 
R
SBE
R
SPE
 100%  
Independent of the LC-ESI-MS interface and ionization method, the recovery measures 
the efficiency of bile acids extraction process during sample pre-treatment. The recovery 
of different bile acids varied from 91% to 109.8%, 86.7% to 99.8% and 91.3% to 111.4% 
under 0.2μmol/L, 2μmol/L and 4μmol/L levels, respectively (Table 2.4). This showed 
that our sample preparation method was adequate to recover bile acids from pouch 
aspiration.  
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Bile Acids 
Concentration 
(μmol/L) Recovery (%) 
CA 0.2 109.8 
2 98.9 
4 108.5 
CDCA 
0.2 91.1 
2 86.7 
4 97.0 
UDCA 
0.2 105.7 
2 99.8 
4 91.3 
DCA 
0.2 91.0 
2 91.5 
4 99.4 
LCA 
0.2 102.7 
2 92.1 
4 107.6 
TCDCA 
0.2 102.5 
2 96.0 
4 109.6 
GCDCA 
0.2 105.8 
2 95.7 
4 111.4 
Table 2.4 Recovery of bile acids at three concentrations (n=3) 
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Accuracy and Precision: Accuracy in terms of percent relative error was determined 
five replicates per concentration for three different QC samples of 0.2, 2 and 4 μmol/L. 
The relative error of the SA-IS method was -7.0% to 12.1%, which was within the 
acceptable values for FDA guideline ( 20% for LLOQ and  15% for all QC samples) 
(Table 2.5). The intra- and inter-assay precision of this SA-IS method were investigated 
by five replicating analysis of the QC samples in triplicate run. The CV % ranged from 
0.8% to 11.4%. The results have shown that this analytical method is accurate and precise 
for the quantification of bile acids in pouch aspiration within the range of 0.05 μmol/L-5 
μmol/L.  
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Table 2.5 Accuracy and intra- and inter-precision in the analysis of bile acids in pouch 
aspiration by the SA-IS method 
 
 
Bile Acids 
Spiked 
Concentration 
(μmol/L) 
Accuracy 
RE(%) 
(n=5) 
Intra-assay 
CV(%) 
(n=5) 
Inter-assay 
CV(%) 
(n=3) 
CA 
0.2 11.1 3.9 4.2 
2 12.1 2.7 7.4 
4 2.7 5.6 6.2 
CDCA 
0.2 9.1 3.8 7.1 
2 9.7 2.2 5.8 
4 0.4 11.4 11 
UDCA 
0.2 -3.1 3.8 4.3 
2 7.8 5.8 9.5 
4 -1.5 7.6 5.6 
DCA 
0.2 1.3 4.7 7.6 
2 8.4 3.8 0.5 
4 -2 3.5 5.9 
LCA 
0.2 2.1 4.3 7.5 
2 1.9 1.5 2.9 
4 -7 4.6 4.6 
TCDCA 
0.2 7.3 4.4 4.5 
2 1.5 3.7 9.4 
4 -2.4 4.1 2.8 
GCDCA 
0.2 8.8 5.7 4.2 
2 7.6 3.1 2.8 
4 0.7 5.3 4.3 
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2.2.3.6. Method application 
 
During the treatment of UC, pouchitis is the most common and non-specific 
inflammatory disease developed in the built ileal pouch after IPAA surgery. Currently the 
diagnosis criteria of pouchitis are mainly based on clinical symptoms and endoscopic and 
histologic value inflammation [5]. To study of the bile acids profile for diseases 
developed after IPAA, we applied the SA-IS method to measure the concentration of bile 
acids in the pouch aspiration samples from the patients diagnosed as pouchitis (No. 570 
and No. 588) and normal pouch (No. 839 and No. 232). The SIM chromatograms 
demonstrated that all bile acids peaks were clearly detected and sufficiently separated 
(Fig. 2.8). Comparing to normal pouch patients, pouchitis patients showed a relatively 
higher concentration of total bile acids and increased ratio of conjugated bile acids (Table 
2.6). However, a broader investigation with more pouch aspiration samples will be 
required in future studies to determine whether the bile acids profile will become a new 
index for the diagnosis of pouchitis. 
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Figure 2.8, Chromatograms of bile acids in pouch aspiration sample No. 588 
 
 86 
 
 
 
 
       a Not detected 
 
Bile Acids 
Class 
Bile Acids 
Found concentrations (μmol/L) 
Pouchitis Normal Pouch 
No. 570 No. 588 No. 839 No. 232 
Primary 
CA 125.5 119.1 114.8 143.5  
CDCA 84.7  124  82.2 120.2  
TCDCA 26.9 48.8  15.3  26.4 
GCDCA 82.5  69.4  18.7  12.3  
Secondary 
UDCA 20.5  41.5 NDa  9.6  
DCA 78.2 58.2 35.6  17.6 
LCA 13.6  35.9  23.8 37.9 
Total Bile Acids (μmol/L) 431.9 496.9 290.4 367.5 
Secondary Bile Acids (%) 26 27.2 20.5 17.7 
Conjugated Bile Acids (%) 25.3 23.7 11.7 10.5 
Table 2.6 Bile acids concentrations in four pouch aspiration samples of patients 
diagnosed as pouchitis and normal pouch after IPAA 
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The SA-IS method developed in this work can potentially be used to study bile acids 
profile in patients with other types of IBD, from whom fecal materials can be collected 
during the routine colonscopic surveillance. In addition, the SA-IS method is accurate 
and robust, thus it can serve as a reference for researchers to develop other technologies 
to profile bile acids in fecal materials. 
 
2.3. Conclusion 
 
Severe matrix effect was observed when quantifying bile acids in pouch aspiration by 
LC-ESI-MS. Ionization suppression caused by co-eluting matrix components varied 
greatly among samples, and it introduced large errors for the measurement using the 
internal standard method. In this study, a standard addition coupled with internal 
standard method has been developed and validated to solve the matrix effect problem. 
We demonstrated that this SA-IS method could effectively correct the ionization 
suppression effect caused by matrix molecules, thus significantly improve the accuracy 
of measurements. To the best of our acknowledge, this is the first study utilizing the 
combination of standard addition and internal standard to correct matrix effect during the 
LC-MS analysis. Compared with existing methods, the SA-IS method involves internal 
standard and simple sample preparation. The method was validated to ensure high 
sensitivity, accuracy, and precision. We have successfully demonstrated its potential use 
in analysis of bile acids in pouch aspiration. The SA-IS method can be a general method 
for bioanalysis in the presence of matrix effect. 
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CHAPTER III 
 
THE DEVELOPMENT OF A ROBUST AND SENSITIVE LC-MS/MS METHOD 
FOR THE QUANTIFICATION OF AN ANTI-CANCER AGENT IN RAT 
PLASMA 
 
 
3.1. Introduction of anti-cancer agent JCC76 
 
In United States, more than 40,000 women die each year from metastatic breast cancer. 
Overexpression of human epidermal growth factor receptor 2 (Her2) occurs in about 
25%-30% metastatic breast cancer. As a member of ErbB family of receptor tyrosine 
kinases [1], HER2 is preferred for ligand binding and the receptor dimerization activated 
multiple downstream signaling cascades, which promote cellular proliferation, survival, 
migration, invasion, and differentiation. HER2 overexpressed breast cancer has an 
increased tendency for metastasis and leads to a relative resistance to same cytotoxic and 
hormone therapy [2,3]. Therefore, HER2 tumors are considered to be more aggressive 
and often have poor prognosis [4]. Previous research showed that the level of HER2 
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expression was closely related to the tumor growth, indicating HER2 as on of the most 
valuable targets for breast cancer therapy [5,6]. 
 
Nimesulide is a nonsteroidal anti-inflammatory drug (NSAIDs) that inhibits 
cyclooxygenase-2 (COX-2) activity. Besides its anti-inflammatory activity, nimesulide 
has been reported to inhibit proliferation and induce apoptosis of a variety of human 
cancer cell lines including lung, ovarian, and breast cancer [7-9]. Other research 
demonstrated that the novel sulfonanilide derivatives of nimesulide significantly 
increased the activity in inhibiting breast cancer cell growth in comparison to that of 
nimesulide [10-11].  JCC76 {Cyclohexanecarboxylic acid [3-(2,5-dimethyl-benzyloxy)-
4-(methanesulfonylmethyl-amino)-phenyl]-amide} is a novel compound deviated from 
nimesulide without COX-2 inhibitory activity [12]. Recently, this lead compound JCC76 
was found to have potent activity against human epidermal growth factor receptor 2 
(HER2) overexpressing breast cancer [10]. 
 
In the in vitro study, JCC76 was found to dramatically inhibit HER2 overexpression cell 
proliferation (i.e., SKBR-3, BT474 and MDA-MB-453 cell lines) [13]. In addition, this 
compound induced apoptosis in HER2 overexpressing cells (i.e., SKBR-3), but it was 
less active in HER2 negative cells (i.e., MCF-7 and MDA-MB-231), which suggested the 
selective inhibition of HER2 overexpressing breast cancer cells [13]. In the in vivo study, 
JCC76 significantly decreased the size of breast tumor in the mice xenograft experiments 
[14]. Based on these results of pharmacological study, JCC76 demonstrated high 
potential to be a target therapeutic agent acting on HER2 positive breast cancer.
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In order to provide insights into the drug developability for targeted breast cancer therapy, 
a quantitative method for JCC76 is needed for the further pharmacological and 
toxicological studies. To date, no analytical assay for JCC76 has been reported. The low 
concentration of JCC76 in blood requires the measurement to be sensitive and specific. 
Because of the multiple blood sampling from a single animal model during a short time, 
only a low volume of sample can be used for each analysis. In previous studies, the 
extraction methods for the class of COX-2 inhibitors, which have similar chemical 
structure with JCC76, employed large amount of sample volume (200 – 500 μL) and 
solvent consumption (4-8 mL), and complex sample pre-treatment procedures of solid 
phase extraction for each analysis [15-17]. 
 
In this work, we have developed a single-step LLE method to clean up the sample matrix 
and to ensure high extraction recovery. The extraction procedure is fast and simple, and it 
consumes less sample volume and solvent. Furthermore, the present study provided a 
short time for each LC-MS/MS analysis and high sensitivity with a lower limit of 
quantification (LLOQ) of 0.3 ng/mL. Finally, we successfully illustrated the preclinical 
application of this method with a pharmacokinetics study of JCC76 in rats. 
 
3.2. Material and methods 
 
3.2.1. Reagents and chemicals 
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JCC76 and IS (compound 75) were synthesized according to previously published 
procedures (Fig. 3.1) [18]. Their purities were higher than 97%, confirmed by NMR and 
HPLC analysis. Methanol, acetonitrile, ethyl acetate, and methyl tert-butyl ether (MTBE) 
of HPLC grade and ammonium formate were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). N-hexane of HPLC grade was obtained from Pharmco-AAPER (Shelbyville, 
KY, USA). Deionized water was purified by Barnstead NANOpure® water purification 
system from ThermoScientific (Waltham, MA, USA).  Pooled blank rat plasma was 
purchased from Lampire Biological Laboratories (Pipersville, PA, USA). 
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Figure 3.1, Chemical structures of JCC76 and the internal standard Compound 75 
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3.2.2. LC-MS/MS instrumentation 
 
The HPLC system consists of two LC-20AD pumps, a DGU-20A3 degasser, a SIL-20AC 
autosampler, and a CBM-20A module (Shimazu, Tokyo, Japan). The chromatographic 
separation was performed on a Luna C18 column (2.0 mm × 150 mm, 5 μm) with a guard 
column (2 mm × 40 mm, 5 μm) from Phenomenex  (Torrance, CA, USA). The mobile 
phase was a mixture of aqueous ammonium formate (pH 3.7; 5 mM)-methanol (1:9, v/v). 
Isocratic elution at a flow rate of 0.2 mL/min was employed. The injection volume was 5 
μL and each run time was 5 min.  
 
The mass spectrometric detection was performed on an AB Sciex QTrap 5500 system 
(AB Sciex, Toronto, Canada) with positive electrospray ionization (ESI
+
). The multiple 
reaction monitoring (MRM) function was used to measure the transition of m/z 445 to 
366.3 and m/z 439.3 to 360.3 for JCC76 and IS, respectively. The optimized parameters 
for detecting JCC76 and IS were set as following: the ion spray voltage was 5500 eV; the 
temperature was at 450 C; the heating gas (GS1), nebulization gas (GS2), and curtain 
gas (CUR) were 30, 40, and 45 psi, respectively. Compound parameters, including 
declustering potential (DP), entrance potential (EP), collision energy (CE), and collision 
exit potential (CXP) for both JCC76 and IS, were set at 60, 10, 21, and 10 V, respectively. 
Data acquisition and quantitation were performed using Analyst software version 1.4.2. 
 
3.2.3. Preparation of calibration standards and QC samples 
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The stock standard solutions of JCC76 and IS were prepared by dissolving each 
compound in acetonitrile at 1 mg/mL and stored at -20C.  One set of JCC76 working 
solutions at 3, 10, 20, 100, 200 and 1000 ng/mL, was prepared by serial dilution from the 
stock solution with water-acetonitrile (1:1, v/v), and then used for preparing the 
calibration standards. Another set of JCC76 working solutions at 3, 9, 90, and 900 ng/mL 
was made in the similar way, and used for preparing QC samples. The working solution 
of IS was prepared by diluting the IS stock solution to 50 ng/mL. All of the working 
solutions were freshly prepared before use. 
 
The calibration standards were prepared by spiking 5 μL of JCC76 working solutions into 
45 μL blank rat plasma to give the final concentration of JCC76 at 0.3, 1, 2, 10, 2 and 100 
ng/mL. The QC samples were prepared in a similar way at 0.3, 0.9, 9 and 90 ng/mL, 
representing lower limit of quantification (LLOQ), low QC (LQC), middle QC (MQC) 
and high QC (HQC) of JCC76 in plasma, respectively. All of the calibration standards 
and QC samples were further treated in the same sample preparation procedure described 
below. 
 
3.2.4. Sample preparation 
 
Aliquots of 50 μL rat plasma sample, from the calibration standards, QC samples and 
pharmacokinetics study samples, were mixed with 5 μL IS working solution (50 ng/mL). 
After vortexing for 10 seconds, the samples went through a single step liquid-liquid 
extraction with 500 μL of an MTBE-hexane mixture (1:2, v/v). After vortexing for 60 s, 
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the mixture was centrifuged at 10,000 rpm for 5 min. Then 420 μL supernatant was 
separated, and evaporated using a centri-vap vacuum evaporation system (Labconco, MO, 
USA). The dry residues were reconsititued in 42 μL 50% acetonitirle for LC-MS/MS 
analysis. 
 
3.2.5. Method validation 
 
Calibration, sensitivity, and selectivity: Calibration curves were constructed by using 
the peak area ratios of JCC76 to IS (y) versus concentrations of JCC76 (x) in the 
calibration standards. The weighted linear regression was generated by using 1/x as 
weighting factor. The LLOQ was determined as the lowest concentration in calibration 
curve that can be quantified with the accuracy and precision within 20%. The selectivity 
of this method was evaluated by testing the presence of the interfering peak in blank 
plasma samples from six different sources. 
 
Matrix effect and recovery: The absolute/relative matrix effect and recovery were 
studied at three QC levels: 0.9, 9 and 90 ng/mL. The absolute matrix effect was 
determined by comparing the peak area of analyte spiked in the post-extraction solution 
of blank plasma with those of standard solution at equivalent concentration. The relative 
matrix effect was studied by comparing the peak area ratio of analyte and IS spiked in the 
blank plasma post-extraction solution with that in standard solution. The post-extraction 
solution was prepared by extracting blank plasma using procedures in section 2.4.  
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The absolute recovery was determined by comparing the peak area of JCC76 spiked in 
plasma before extraction with that in post-extraction spiked sample. The relative recovery 
was determined by comparing the peak area ratio of JCC76 to IS spiked in plasma before 
extraction with that in post-extraction spiked sample. 
 
Accuracy and precision: Intra- and inter-assay precision and accuracy were assessed 
using QC samples at four different concentrations: LLOQ, LQC, MQC and HQC. Intra-
assays were carried with five replicates (n=5) for each concentration in the same day, 
while inter-assays were performed with five replicates (n=5) in different days. The 
precision results were expressed as percent relative standard deviation (% RSD) and the 
accuracy results were expressed as percent relative error (% RE).  
 
The dilution QC was also prepared to study the accuracy and precision in cases when 
samples concentration was above the highest concentration of the calibration curve. The 
dilution QC samples (n=5) contained were prepared by spiking JCC76 into blank rat 
plasma at 900 ng/mL, and then were 10 times diluted with blank rat plasma before 
extraction. Following the same sample preparation procedures, the dilution QC samples 
were analyzed and their concentrations were compared with the nominal concentration. 
 
Stability: The storage stability was investigated with blank plasma spiked with JCC76 at 
LQC level (0.9 ng/mL) and HQC level (90 ng/mL) in triplicates going through the 
following conditions: sitting in room temperature for 4, 6 and 24 hr, three freeze-thaw 
cycles, -20C for 30 days, and post-extraction storage at 4C for 24 hr. For the freeze-
 101 
thaw stability study, the spiked samples were subjected to three freeze (-20C)-thaw 
(room temperature) cycles and each cycle was 24 hr. 
 
3.2.6. Pharmacokinetics study 
 
The feasibility of this quantitative method was tested through a pharmacokinetics study 
of JCC76 in rats. Male Sprague–Dawley rats (each weight 300 – 350 g) were purchased 
from Charles River Laboratories International (Spencerville, OH, USA). The animals 
were housed in a 12 h light/dark cycle room with free access to food and water for at least 
7 days to adapt to the environment. All the animal experiment procedures were 
performed under the guideline approved by Institutional Animal Care and Use 
Committee at Cleveland State University.  
 
Before the intraperitoneal(i.p) administration of JCC76 at a single dose of 5 mg/kg, 
animals were fasted overnight but with free access to water. Blood samples of 150 μL 
each time point were collected from the saphenous veins and femoral veins into 
heparinized tubes at 0 hr (before drug administration) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 
and 8 h after dosing. The blood samples were centrifuged immediately at 10,000 rpm for 
5 min in room temperature. The plasma samples were separated and store at – 20 C until 
analysis.  
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The concentration of JCC76 in rat plasma versus time profiles were analyzed to estimate 
pharmacokinetics parameters using WinNonlin® software version 5.2 (Pharsight 
Corporation, Mountain View, CA, USA). 
 
3.3. Results and Discussion 
 
3.3.1. Mass spectrometric and chromatographic conditions 
 
In order to optimize the MS parameters, we introduced standard JCC76 and IS in 90% 
methanol at 200 ng/mL through infusion into the mass spectrometer at 10 μL/min. The 
mass spectra from full positive scan of JCC76 and IS showed the protonated molecules 
[M+H]
+
 with m/z 445.3 and 439.3, respectively. The most abundant product ion after 
fragmentation was at m/z 366.3 for JCC76 and m/z 360.3 for IS (Fig. 3.2). The 
fragmentation reactions for both compounds were proposed as the loss of SO2CH3 by 79 
u. As a result, the ion detection employed multiple reaction monitoring (MRM) mode 
with selecting the transition of m/z 445.3 366.3 for JCC76 and m/z 439.3  360.3 for 
IS. The collision energy, spray voltage, and ion-spray voltage were fine-tuned to obtain 
the highest MS response.  
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Figure 3.2, The precursor/product ion spectra and proposed fragmentation  
pathways for (A) JCC76 and (B) the internal standard compound 75 
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The solubility of JCC76 is poor in water with a predicted high Log D value of 4.86. 
Therefore, we chose to use a large portion of methanol in the mobile phase to elute the 
compound from a C18 column. Since the addition of organic acids promotes the 
protonation of the analyte under positive ESI, several mobile phase modifiers including 
formic acid, acetic acid, ammonium formate, and ammonium acetate with different 
concentrations were tested to optimize the chromatographic results. We observed that 
mobile phase consisting of 5mM ammonium formate-methanol (1:9, v/v) yielded the 
highest MS response of JCC76, which increased by 2 folds comparing water-methanol (1: 
9, v/v) without any modifier. The retention times were 3.04 min for IS and 3.5 min for 
JCC76 by the isocratic elution. Using the above mobile phase, the peaks of analyte and IS 
were symmetrical, the sensitivity was improved, and the total run time was controlled 
within 5 min. 
 
3.3.2. Sample extraction 
 
PPT has been used extensively for the preparation of plasma samples because of its 
simplicity [19]. To simplify our sample extraction technique, the PPT method for plasma 
cleaning-up was tested, but matrix suppression of 30%-33% was observed. Adding acetic 
acid or formic acid into rat plasma prior to the PPT pre-treatment could relieve the ion 
suppression of the analyte by 6-8%. However, it decreased the extraction recovery by 13-
16%. LLE was reported to be more efficient and to provide cleaner extracts than PPT and 
the SPE for sample preparation in most cases [20]. Much effort was put into finding an 
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optimal extraction solvent with high extraction efficiencies and minimal matrix effect for 
JCC76. 
 
We tested extraction solvents ranged from polar to non-polar, which included ethyl 
acetate, chloroform, methyl chloride, diethyl ether, MTBE, and hexane. Among theses 
solvents, non-polar ones including MTBE and hexane have much higher extraction 
recovery than other solvents for JCC76 (Fig. 3.3), which implies that the non-polar 
solvents favored the extraction for hydrophobic compounds. Regarding the matrix effect, 
the extraction with MTBE yielded the lowest ion suppression, which agreed with other 
reports that suggested MTBE is especially efficient in reducing matrix effect by removing 
the phospholipids in plasma [21]. Based on these observations, parallel extraction 
experiments based on different ratios of MTBE and hexane mixtures were performed. 
Finally, we observed that the optimized solvents mixture consisted of MTBE-hexane (1:2, 
v/v) (Fig. 3.4). This LLE method produced reproducible results of matrix effect less than 
10% and high recovery above 90% for the extraction of JCC76 from rat plasma. The 
extraction procedure is simple, and it uses small amounts of solvent and sample volume.  
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Figure 3.3, The comparison of matrix effect and recovery of JCC76 in rat 
plasma among different LLE solvents. Each column represents the mean ± 
S.D. (n = 3) 
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3.3.3. Method validation 
 
3.3.3.1. Linearity, sensitivity, and selectivity 
 
JCC76 calibration curves were established using double blank (blank plasma sample with 
neither JCC76 or IS), zero blank (blank plasma with IS only), and six non-blank 
calibration standards at the concentrations of 0.3, 1, 2, 10, 20, and 100 ng/mL. The IS 
concentration in zero blank and the calibrations standards was 5 ng/mL. The peak area 
ratio of JCC76 to IS (y) versus JCC76 concentration (x) was plotted using 1/x as 
weighting factor. The linear regression equation (the slope and intercept in the mean ± 
SD) obtained in five different days was y = (0.192  0.002)x + (0.00054  0.0006). The 
linearity was excellent over the range of 0.3-100 ng/mL with the correlation coefficients 
above 0.9993 for all calibration curves built in different days.  Accuracy and precision of 
all calibrators were within 15% (Table 3.1). As the lowest concentration on the 
calibration curve, the LLOQ was 0.3 ng/mL.  It was sufficient to determine the 
concentration of JCC76 in rat plasma for pharmacokinetic study. 
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Table 3.1 Accuracy and Precision of JCC76 calibration standards over 0.3 - 100 ng/mL  
 
Nominal 
Concentration 
Determined 
Concentration 
Accuracy % Precision % 
0.3 0.29  0.007 -3.3% 3.9% 
1 0.98  0.017 -2.3% 1.7% 
2 1.89  0.138 -5.8% 7.3% 
10 10.15  0.084 1.5% 0.8% 
20 19.70  0.310 -1.5% 1.6% 
100 100.28  3.581 0.3% 3.6% 
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The selectivity was investigated from blank plasma from six different sources. LC-
MS/MS chromatograms of blank plasma, blank plasma spiked with JCC76 and IS, and a 
rat plasma sample after i.p. administration of JCC76 were compared (Fig. 3.4). No 
endogenous inferences at the retention times at 3.5 min for JCC76 and at 3.04 min for IS 
were found in six different blank plasma samples, indicating high selectivity and 
specificity of this method for the analysis of JCC76 in rat plasma matrix.  
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Figure 3.4, The MRM chromatograms of (A) blank rat plasma, (B) blank plasma 
spiked with JCC76 at LLOQ level (0.3 ng/mL 3.54 min) and IS (5 ng/mL, 3.02 min), 
and (C) a real rat plasma sample collected 8 hr after an i.p. administration of  5 mg/kg 
JCC76 spiked with IS 
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3.3.3.2. Matrix effect and recovery 
 
The matrix effect and extraction recovery was further evaluated at three levels: 0.9, 9, 
and 90 ng/mL. As shown in Table 3.2, the absolute matrix effect at three concentrations 
ranged from 3.1% to 9.2%, and the relative matrix effect ranged from -6.1% to 4.3%, 
indicating no obvious signal suppression or enhancement for the ionization of JCC76 in 
rat plasma matrix. The extraction of JCC76 at three levels showed absolute recovery of 
89.5% to 97.3% and relative recovery of 105.1% to 106.1% after the IS normalization. 
The results indicated that the extraction procedure was not only sufficient to remove the 
interference impurities from the sample matrix. 
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Table 3.2, Absolute and relative matrix effect and recovery of JCC76 in rat plasma 
 
Concentration 
(ng/mL) 
Matrix Effect  Recovery 
Absolute 
ME 
Relative ME  
Absolute 
Recovery 
Relative 
Recovery 
0.9 3.1% -6.1%  96.9% 106.1% 
9 8.8% 3.7%  89.5% 105.1% 
90 9.2% 4.3%  97.3% 105.1% 
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3.3.3.3. Accuracy, precision, and dilution integrity 
 
As the results shown in Table 3.3, the inter- and intra-assay accuracy and precision were 
within  10%, indicating the this method is accurate, precise, and reproducible. Since 
some samples containing JCC76 above the highest concentration of calibration curve, we 
also investigated the accuracy and precision after ten times dilution of dilution QC by 
blank sample matrix. The results showed that the intra- and inter-accuracy of the dilution 
samples were -0.1% and 2.1%, respectively. The intra- and inter-precision results were 
0.8% and 1.6%. This result suggests that the plasma sample can be diluted and then 
analyzed when the concentration of JCC76 is above the upper limit of calibration.  
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Table 3.3, Intra- and Inter- assay accuracy and precision of JCC76 in rat plasma 
 
 Intra-assay  Inter-assay 
 Nominal 
(ng/mL) 
Determined 
(ng/mL) 
Accuracy 
%RE 
SD 
Precision  
%RSD 
 
Determined 
(ng/mL) 
Accuracy
 %RE 
SD 
Precision 
%RSD 
0.3 0.297 -1.1% 0.004 1.4%  0.301 0.3% 0.010 3.3% 
0.9 0.870 -3.3% 0.010 1.1%  0.915 1.7% 0.072 7.9% 
9 8.63 -4.1% 0.095 1.1%  9.04 0.5% 0.395 4.4% 
90 84.2 -6.5% 1.272 1.5%  87.3 -3.1% 2.481 2.8% 
900 899 -0.1% 7.483 0.8%  919 2.1% 14.618 1.6% 
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3.3.3.4. Stability 
 
The results of the stability tests were summarized in Table 3.4. At room temperature, 
JCC76 was found to be stable for at least 24 h. The post-extraction stability study of 
JCC76 indicated its stability in the reconstitution solvent for at least 24 h. After three 
freeze-thaw cycles, the recovery of JCC76 was 78.2 % at LQC and 85.5 % at HQC levels. 
The long-term storage stability for JCC76 at -20 C for 30 days was 89.2 % and 79.3% at 
LQC and HQC levels, respectively. 
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Table 3.4, Stability test of JCC76 in rat plasma 
 
Storage Conditions Concentration 
(ng/mL) 
Recovery 
% 
At room temperature for 4 hr 0.9 99.3% 
 90 95.3% 
   
At room temperature for 6 hr 0.9 92.3% 
 90 90.4% 
   
At room temperature for 24 hr 0.9 99.9% 
 90 99.2% 
   
Three freeze-thaw cycles 0.9 78.2% 
 90 85.5% 
   
Post-extraction at 4°C for 24 hr 0.9 97.6% 
 90 101.2% 
   
Long-term stability (at -20°C for 30 days) 0.9 89.2% 
  90 78.3% 
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3.3.3.5. Pharmacokinetic study 
 
The feasibility of this method was tested by the application of a preclinical 
pharmacokinetics study in rats. The mean JCC76 concentration in plasma versus time 
profile was presented in Fig. 3.5. The maximum concentration of JCC76 (Cmax) in plasma 
was 528 ng/mL, which was reached at 0.5 h (Tmax) after dosing. The pharmacokinetics 
parameters were estimated through compartmental analysis and the concentration – time 
profile was found to fit a two-compartment model. The estimated AUC0-, total body 
clearance, and volume of distribution were 1962 (ngh)/mL, 2.5 L/(hkg), and 7.0 L/kg, 
respectively. 
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Figure 3.5, Mean plasma concentration-time profile of JCC 76 after the i.p. 
injection of JCC 76 at a single dose of 5 mg/kg. Each point represents the mean 
± S.D. (n = 4) 
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3.4. Conclusion 
 
In the presented work we have developed and validated a LC-MS/MS method for the 
quantification of JCC76 in a biological matrix for the first time. This method is simple, 
sensitive, and specific for the analysis of JCC76 in rat plasma. It used a one-step liquid-
liquid extraction for sample preparation and a short time for LC-MS/MS analysis. The 
LLOQ of this method was as low as 0.3 ng/mL and the accuracy and precision were 
lower than 10%. The stability tests were performed under different storage and handling 
conditions and the results showed the suitability of this method for high throughput 
routine analysis. We have successfully applied this method in the determination of JCC76 
in rat plasma for the pharmacokinetics study. This method will be further used in 
pharmacokinetics and toxicokinetics studies in animals in the future. It could be valuable 
for supporting the new drug investigation and application. 
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CHAPTER IV 
 
 
PROTEOMICS STUDY FOR POTENTIAL BIOMARKER ANALYSIS OF 
OVARIAN CANCER 
 
 
4.1. Introduction 
 
Ovarian cancer is the leading cause of death from gynecological malignancies worldwide. 
The lifetime risk of ovarian cancer for women is about 1.6% and the risk increases with 
age and deceases with pregnancy. The majority of ovarian cancers tend to present as 
advanced stage, resulting in as high mortality rate as 56% [1,2].  
 
The International Federation of Obstetrics and Gynecology (FIGO) staging system 
describes the early stage (stage I and II) and advanced stage (stage III and IV) of ovarian 
cancer as follows: stage I disease involves one or both ovaries; stage II disease is defined 
as the spread tumor limited to pelvis; stage III disease involves the spread tumor with 
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peritoneal implants; and stage IV tumor is the distant spread tumor of metastasis [3, 4]. 
The early diagnosis of ovarian cancer can increase survival significantly. When the tumor 
is still confined to the ovary in early stage, detection and surgical removal of cancerous 
tissues result in cure for over 90% patients [3]. However, the ovary is not symptomatic in 
the stage I and II. Compared to breast, prostate, and colon cancer, ovarian cancer is 
anatomically more difficult to be assessed during physical examination due to the 
location of the ovary. Therefore, a very promising approach to improve the mortality rate 
for ovarian cancer is to discover reliable biomarkers and to develop adequate sensitive 
and specific screening test for early detection.  
 
The biomarkers associated with the development of ovarian malignancy have been 
investigated in blood, tissue, and other biofluids using DNA microarrays and proteomics. 
With advantages in characterizing post-translation modifications of proteins, proteomics 
is believed to be one of the most attractive approaches for biomarker discovery. The 
technological obstacles of proteomics profiling for ovarian cancer include the lack of 
sensitivity of mass spectrometric detection, the mask of low-molecular weight proteins by 
the abundant proteins, and the discrimination of ovarian carcinoma from benign tumors.  
 
The only approved serum biomarker CA-125 has been used for remission monitoring of 
ovarian cancer, but not for screening. It fails to reach the sensitivity and specificity for a 
screening test of early stage ovarian cancer detection. The elevated level of CA-125 was 
found in approximately 80%-85% of patients with advanced stage ovarian cancer, but in 
only 50% of patients in early stage [5]. In addition, elevated levels of CA-125 are also 
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associated with a variety of other conditions including other cancers (pancreatic, breast, 
bladder, liver and lung), benign and malignant breast and colon diseases, peritoneal 
irritants, and benign gynecologic diseases [6-8]. Nevertheless, new technologies in mass 
spectrometry for discovering other novel proteomics markers are emerging, aimed to 
improve the sensitivity and specificity of current screening tests. 
 
Due to the dynamic range of proteins present in the serum, high abundance proteins were 
removed to increase the possibility of low molecular weight protein detection. Matrix-
assisted desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) has 
been used as an fundamental tool for proteomic study for its efficiency in detecting 
peptides as low as 1 femtomole [9]. In addition, there is no mass range limitation for the 
MALDI-TOF analysis and it is preferable for fast analysis, allowing 100 samples to be 
finished in less than 10 min [10]. For these major advantages, MALDI-TOF-MS was 
used for the quick scan of large biomolecules existed in serum samples from ovarian 
cancer patients. Our group reported differentiated mass spectra derived from cancer 
patient and normal sera by MALDI-TOF-MS analysis for three major peptide peaks of 
1260, 1465, and 1545 Da [11] (Fig. 4.1).  
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Figure 4.1, Previous reported analysis on MALDI-TOF-MS pattern for 
ovarian cancer patient and normal control samples [11]. 
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Based on these previous findings, comparative analysis of low molecular weight protein 
profiling was further preformed by LC-MS/MS in this work. Several sets of samples from 
patients with ovarian carcinoma, benign tumors, and healthy normal controls were 
examined to identify carcinoma-associated proteins or peptides as valuable biomarkers 
for ovarian cancer progression. One of the major MS peaks, which discriminated normal 
control with cancer patients in MALDI-TOF scanning, was defined by LC-MS/MS 
analysis. The developed LC-MS/MS method greatly improved the reproducibility in 
peptides profiling. In addition, the protein fractionation method was refined in terms of 
higher extraction efficiency and less impurities. At last, the discovered biomarker was 
validated in benign and carcinoma samples for the improvement of early detection.  
 
4.2. Materials and Methods 
 
4.2.1. Materials 
 
Acetonitrile and chloroform of HPLC grade, TFA, and formic acid were purchased from 
Sigma-Aldrich Chemical (St Louis, MO, USA). Deionized water was generated by a 
Millipore water purification system (Billerica, MA, USA). Phosphate-buffer saline (PBS) 
solution was purchase from BIO-RAD (Hercules, CA, USA). 
 
4.2.2. Patient samples 
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Human serum samples from healthy individuals were purchased from Sigma-Aldrich (St 
Louis, MO, USA). The serum samples from patients diagnosed with advanced stage 
ovarian cancer of carcinoma (N=40) and benign diseases (N=20) were obtained from 
Gynecologic Oncology Group (GOG) tissue bank (Buffalo, NY, USA). Among the forty 
carcinomas samples, there were twenty papillary serous carcinomas, ten mucinous 
carcinomas, five endometrioid carcinomas, and five clear cell carcinomas; As the twenty 
benign samples, there were ten serous benign, five mucinous benign, and five other 
benign. This project was approved by the Institutional Review Board at Cleveland State 
University. 
 
4.2.3. Serum peptide fractionation 
 
The low molecular weight peptides were separated from the abundant proteins in serum 
by protein precipitation. An aliquot of 40 μL serum was mixed with 1 mL 90% methanol 
in water. After vortexing for 1 min, the mixture was centrifuged at 10,000 rpm by a 
Beckman Coulter Allegra
TM
 X-22R Centrifuge for 5 min to precipitate the proteins. The 
clear supernatants were removed and then evaporated to dryness by centri-vap vacuum 
evaporation system (Labconco, MO, USA). The dry residues were re-dissolved in 400 μL 
water. Afterward, the solution was cleaned by adding 200 μL chloroform for liquid-liquid 
extraction. The chloroform phase and aqueous phase were well mixed by vortexing for 2 
min. The mixture was centrifuged at 10,000 rpm for 5 min and the upper layer was 
carefully removed. After evaporating and concentrating the sample to 60 μL, an aliquot 
of 10 μL solution was injected to the LC-MS/MS system for analysis. 
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4.2.4. Online peptide trap setup 
 
Prior to the micro-flow LC separation, the injected peptide sample was cleaned and de-
salted by an online peptide trap setup. As illustrated in Fig. 4.2, at the sample loading 
position, the trap peptide cartridge (CapTrap, Michrom) was connected with sample 
injector; at sample elution position, the peptide trap was connected with elution buffer 
pump and capillary HPLC column. After the sample was loaded into the peptide trap in 
10 min, the column switch was changed to sample elution position. The switched elution 
buffer eluted the sample from the trap to the HPLC column.  
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Figure 4.2, Online peptide trap setup 
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4.2.5. Serum protein analysis by LC-MS/MS 
 
The micro-LC-MS/MS system consisted of an Aglient 1100 HPLC, an online-extraction 
system, and a Bruker HCT 3000 plus ESI IonTrap Mass Spectrometer. The 
chromatographic separation of peptides was carried out on a Vydac C18 capillary reverse 
phase HPLC column (100 mm × 300 μm ID, 5 μm) at room temperature (23°C). The 
mobile phase used 0.1 % formic acid in water: acetonitrile (99:1, v/v) as aqueous phase A 
and 0.1% formic acid in water: acetonitrile (1: 99, v/v) as organic phase B. The following 
gradient elution program was applied for all the peptide analysis: at the beginning of LC, 
2% B was hold for 10 min, then increased to 90 % B in 70 min, following by maintaining 
90% B for 20 min, and at last returned to 2% B for 10 min for re-equilibration. The flow 
was maintained at 5 μL/min through the analysis. 
 
The mass spectrometer was operated in positive ESI mode. MS/MS data were acquired at 
a scanning mode of standard-enhanced at a range of 350- 1500 m/z. The nebulization gas, 
drying gas, and dry temperature were set as: 11 psi, 5 L/min, and 300 °C, respectively. 
The tandem MS data were used to search matched peptide fingerprints against NCBInr 
protein database by Mascot Program (http://www.matrixscience.com). The following 
searching parameters were applied: no trypsin, no taxonomy or modification, peptide 
mass tolerance is ± 1.0 Da, MS/MS tolerance is ± 0.5 Da, all possible charge states (i.e. + 
1, +2, and +3), and a mass window between 0 and 100 kDa. To reduce the number of 
false-positive signals, only significant hits with at least 4 matching peptide masses were 
considered as final results. 
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4.3. Results  
 
4.3.1. Identification of differentially expressed low molecular weight peptides  
 
Based on the results of MALDI-TOF-MS pattern analysis reported previously [11], the 
clinical serum samples of 20 ovarian caner patient and 18 normal healthy controls 
generated a panel of biomarkers. By comparing the typical MS pattern, significant 
differences were observed regarding three peaks with the following m/z: 1465 Da, 1260 
Da, and 1535 Da [11].  However, this method is poor in reproducibility and is not able to 
identify the peptide with corresponding MS spectra.  
 
To compensate for this disadvantage, ESI-MS was used for improving the reproducibility 
in this study since no crystallization process during ionization is involved in ESI 
compared to MALDI.  The mass spectrometer generated the spectra of both precursor 
ions and fragmentation ions, which were further analyzed by the computer to search for 
matching protein information in the database. Since HPLC was often necessary to 
separate the complex proteomic sample prior to the MS analysis, we conducted capillary 
LC to analyze pre-fractionated serum samples from ovarian cancer patient group and 
normal control group.  
 
Initially, the mixture of six patient samples and the mixture of six ovarian cancer patient 
samples were analyzed. From the resulting chromatograms, we noted that the major 
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difference between these two sample mixtures was a peak appearing at 42 min in cancer 
group but not in control group (Fig. 4.3). In the averaged MS spectra generated by this 
characteristic peak, the double charged MS peak of m/z 733 had the highest signal 
intensity. This finding was consistent with the result from previous MALDI-TOF-MS 
analysis, which showed the most abundance peptide peak at 1465 Da.  
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Figure 4.3, Differentiated LC-MS/MS chromatograms from ovarian cancer 
group (top) and control group (bottom) 
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Further, the mascot database searching was applied using the MS/MS peptide data 
acquired from the ovarian cancer sera sample. The matched peptide information was 
identified as des-alanine fibrinopeptide A (des-alanine-FPA) with the sequence of 
DSGEGDFLAEGGGVR. Des-alanine-FPA is derived from FPA by losing an amino acid 
and its molecule weight is 1465 Da. Interestingly, we did not find the intact FPA of 1535 
Da in neither the cancer patient samples nor in the normal healthy individuals. By 
carefully looking at the results of Mascot searching, we found that the des-alanine-FPA 
fragment fingerprints matched up with the MS spectra of peak eluting at 42 min in 
ovarian cancer serum sample (Fig. 4.4).  
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Figure 4.4, The MS spectrum of chromatographic peak eluting at 42 min, 
with matched MS information with des-alanine-FPA 
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4.3.2.    Protein fractionation method by organic solvent precipitation 
 
Previously our group has successfully removed the abundant proteins by utilizing 80% 
acetonitrile solution and obtained better prefractionation results compared to centrifugal 
ultrafiltration. To further optimize this sample preparation method, we compared the 
signal intensity of des-alanine-FPA in the supernatants after 80% acetonitrile 
precipitation and 90% methanol precipitation. The results indicated that 90% methanol 
precipitation yielded higher intensity of des-alanine-FPA and its fragments in the MS 
spectrum, suggesting a better recovery of this biomarker.   
 
The MS and MS/MS spectra were examined from the whole gradient program to find out 
when des-alanine-FPA was mainly eluted. This potential biomarker was separated from 
other hydrophobic components, which were mainly eluted out at the end of elution 
program with high percentage of organic phase. However, the full scan chromatogram 
indicated that the intensity of des-alanine-FPA was much lower than these components. 
These hydrophobic components may overload the reverse phase column and decrease the 
efficiency of chromatographic separation after a few continuous injections. To prevent 
the reduction of column robustness, we added a liquid-liquid extraction procedure to 
remove hydrophobic components after organic solvent precipitation.  
 
The supernatants after 90% methanol precipitation were subjected to a liquid-liquid 
extraction method using chloroform as the extracting solvent. By comparing the 
chromatograms with and without chloroform extraction, the MS total ion chromatograms 
of ovarian cancer serum sample showed much lower intensity of hydrophobic 
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components, but without much effect on des-alanine-FPA level (Fig. 4.5). In addition, we 
did not observe any decrease in the resolution and intensity of the differentiated 
chromatographic peaks in five continuous injections. It proved that the liquid-liquid 
extraction method was effective to reduce the complexity of serum by removing partial 
hydrophobic components.  
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Fig. 4.5, Improvement of chromatograms by adding a chloroform-water 
extraction procedure into the sample preparation. Blue line indicate sample 
without chloroform-water extraction and black line indicate sample with 
chloroform-water extraction. 
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4.3.3.    LC-MS/MS analysis of different sample sets 
 
 
Given the finding of des-alanine-FPA as a potential biomarker by LC-MS/MS analysis, 
we further evaluated this biomarker in each serum sample of the patients with carcinoma, 
patients with benign conditions, and healthy control. The tandem MS information for 
each sample was processed and used for the searching of the des-alanine-FPA 
fingerprints. 
 
The criteria to confirm whether des-alanine-FPA exists in different samples include the 
MS/MS database search and the elution time at 42 min. Des-alanine-FPA peak was 
predominantly found in both the benign and carcinoma groups. Analysis of 20 benign 
samples yielded detectable des-alanine-FPA peak in 16 samples with the percentage of 
80%. Among the 40 carcinoma samples subjected to analysis, 37 samples were observed 
with des-alanine-FPA peak, indicating the sensitivity of this biomarker as 93%. With 
regarding to the control group, we observed that three samples (N=20) showed des-
alanine-FPA signal and all other samples had negative results, suggesting a good 
specificity result of 85%. 
 
Considering half of the malignant tumors are transformed from the pre-existing benign 
cysts, the up-regulated des-alanine-FPA appearing in a high percentage of benign set is 
not surprising. However, when comparing the peak area or signal intensity of des-
alanine-FPA peak in the benign and carcinoma sets, we did not observe any significant 
difference on its expression levels to discriminate these two sets. This is possible if des-
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alanine-FPA is not only involved in the slow growth of pre-malignant lesions before 
carcinogenesis, but also is associated with the fast transformation of normal ovary to 
carcinoma.  
 
4.4. Discussion 
 
In this study, we demonstrated a LC-MS/MS method for the low molecular serum protein 
profiling in the biomarker discovery of ovarian cancer. One of the obstacles for protein 
biomarker discovery in serum is the dynamic range of protein components. To overcome 
this problem, extensive pre-fractionation steps were usually needed to increase the 
likelihood of low abundance biomarker detection. It has been reported that organic 
solvent precipitation was used to extract low molecular weight protein in human serum 
samples [12]. Compared to other methods, organic solvent precipitation method is simple, 
convenient, and processes high recovery for low abundance peptides.  
 
The sample pretreatment method utilized in this work was modified based on previous 
reports. It improved reproducibility and sensitivity by reducing the hydrophobic residues 
in the serum sample solution after the depletion of high abundance proteins. The 
developed LC-MS/MS method showed that the chromatogram of serum low molecular 
weight peptides differentiates from ovarian cancer patients to healthy control in a major 
marker peak. Further, this peak was characterized as des-alanine FPA, which is derived 
from fibrinopeptide by losing an amino acid of alanine. 
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Fibrinopeptide A (FPA) is generated from fibrinogen by thrombin during blood 
coagulation. Thrombosis and disseminated intravascular coagulation are common 
complications of cancer, and such a procoagulant state in cancer arises mainly from the 
capacity of tumor cells to express and release procoagulant factors. It has been reported 
that FPA related peptides were up-regulated in different type of cancers including ovarian 
cancer [13-16]. In addition, there was finding of elevated phosphor-FPA as post-
transcription modification in serum of advance staged ovarian cancer samples [13]. These 
findings revealed a high degree of biological relevance between cancer and fibrinogen 
fragments. However, the mechanism of high level des-alanine-FPA and its correlation 
with ovarian cancer has not been reported yet. It is essential to carry out a careful follow-
up validation using rational and rigorous methodology for ovarian cancer biomarker 
discovery. 
 
In the validation of des-alanine-FPA level in the sample with different sets of ovarian 
cancer diseases, we found that both benign and carcinoma sets had up-regulated des-
alanine-FPA expression compared to normal control. The challenge of differentiating 
benign tumors with malignant carcinoma for ovarian cancer screening remained in this 
work. We have not found any relation between the level of this biomarker to define 
different disease states such as benign and carcinoma.  
 
Serum was used as the sampling source in this study because it contains the circulating 
proteins and peptides shed from cancerous cells and tissues into blood. Compared to 
plasma, it is less complex due to the coagulation process and the removal of clotting 
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factors during specimen collection. Serum is generally used as an acceptable starting 
material for many diagnostic assays and proteomics investigations. However, the serum 
sampling process usually requires the coagulation process of whole blood for 30-45 min, 
which initiates a cascade of enzymes reactions such as the formation of solid fibrin by 
serine proteases. During this clotting process, FPA is removed from the n-terminal 
segment of the alpha chains of fibrinogen by the thrombin. We were concerned that the 
FPA level and especially des-alanine-FPA level could be affected by clotting process of 
serum sampling. Variability introduced through sample collecting and storage can be 
misinterpreted as des-alanine-FPA level changes resulting from ovarian tumorigenesis.  
 
Consequently, further study should be carried out in examining whether the specimen 
sampling and storage as well as our current sample preparation method affect the des-
alanine-FPA level. More importantly, the verification of the des-alanine-FPA level in the 
plasma is essential to move this work forward. Compared to serum, the sample source of 
plasma avoids the specimen-to-specimen variation of clotting extent and duration and 
could better represent real blood proteomes.  
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CHAPTER V 
 
 
COMPREHENSIVE ANALYSIS OF TUMOR-ASSOCIATED DNA 
METHYLATION IN HEPATOCELLULAR CARCINOMA 
 
 
5.1. Introduction 
 
Hepatocellular carcinoma (HCC) is the one of the most aggressive malignancies with the 
third mortality among cancer worldwide [1]. Highly prevalent in Asia and Africa, HCC is 
recently reported to be on the rise in many developed countries including United States, 
Japan, and Western Europe [2]. The clinical management of HCC, depending on its stage, 
includes curative approaches such as resection, orthotopic liver transplantation, local 
ablation, radioembolization, and sorafenib treatment [3]. Despite significant advances in 
HCC management, the survival rate of HCC is low due to its poor diagnosis and 
prognosis, high recurrence, and resistance to chemotherapy and radiotherapy [4]. 
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The major etiological risk factors of HCC for cancer development have been well 
understood. These factors include hepatitis virus infection, chronic alcohol consumption, 
liver cirrhosis, and aflatoxin intake [5,6]. However, the majority of HCC were detected in 
non-resectable advanced stages, which prevents potential curative treatments.  
 
The early diagnosis of HCC presents a lot of challenges since the imaging techniques 
such as CT and MRI scan are not adequate to distinguish HCC with long-term liver 
cirrhosis [7]. The most commonly used tumor biomarker α-fetoprotein (AFP) is helpful in 
the surveillance tests, but its use is also controversial because of lacking diagnostic 
accuracy and sensitivity [8]. Other serum biomarkers such as lectin-bound AFP, or des- 
carboxy-prothrombin (DCP) have large limitations because they are not consistent or 
particularly precise for the early diagnosis of HCC [9]. Therefore, it is urgent to develop 
novel biomarkers for the early detection of malignancy of hepatocytes for better 
screening tests. 
 
The carcinogenesis for HCC development involves complicated genetic and epigenetic 
changes. Genomic alterations such as gene mutations, chromosomal amplifications and 
deletions, and unstable genomics were closely associated with HCC [10,11]. In addition, 
epigenetic alterations, including DNA methylation, histone modification, and altered 
expression of chromatin-modifying enzymes were also frequently observed in malignant 
transformation of hepatocytes as an alternative pathway [12]. Aberrant gene methylation 
has been well documented as the best-known epigenetic event in different cancers 
including HCC [13,14]. When DNA methylation occurs in CpG dinucleotides, a methyl 
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group from S-adenosyl methionine (SAM-CH3) is added at the carbon five position of the 
cytosine ring through covalent bond (Fig. 5.1). This reaction is catalyzed by DNA 
methyltransferases 1, 3a, or 3b (DNMT).  
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Figure 5.1, Cytosine methylation catalyzed by DNMT 
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In cancers, global hypomethylation causes the instability of chromosomes and local 
changes of promoter methylation (hypermethylation) of CpG islands in tumor suppressor 
genes lead to transcriptional silencing [15,16]. Besides the direct inactivation of tumor 
suppressor genes, DNA hypermethylation can also block transcription factors and silence 
DNA repair genes, resulting in the loss of downstream gene functions and the 
accumulation of genetic lesions [17].  
 
In HCCs, a growing number of genes with aberrant DNA hypermethylation have been 
identified. Epigenetic silencing of the tumor suppressors RASSF1A and p16 (CDKN2A) 
were frequently reported in previous studies. Hu L et al. detected the promoter 
hypermethylation of RASSF1A in both serum and tissue DNA in HCC [18]. Similarly, 
Formeister et al. reported the increased methylation of RASSF1A, p16 (CDKN2A), APC, 
GSTP1, and RIZI in tumorous tissues comparing with adjacent non-tumorous HCC 
tissues [19]. In addition, this phenomenon has been observed in the non-cancerous 
cirrhotic tissues of HCC patients, supporting that the hypothesis that epigenetic 
inactivation is an early event of HCC [20]. These findings help the understanding of 
hepatocarcinogenesis in early stage and support the potential biomarker discovery for 
early diagnosis through methylation alterations.  
 
The RASSF1A gene is one major isoform of Ras-Association Domain Family 1 
(RASSF1). It maintains the genomic stability and modulates a broad range of cellular 
functions including apoptosis, cell motility and invasion for normal cell functions [21]. 
The expression of RASSF1A is ubiquitous in non-cancerous tissues, but is reduced in 
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cancer cell lines and tissues. Mice with knocked out RASSF1A gene has the tendency to 
develop tumors, correlating impaired RASSF1A expression with tumorigenesis [22]. The 
lost of RASSF1A function has been found in 37 tumor types due to the promoter 
methylation [23].  
 
P16 is a cyclin-dependent kinase inhibitor (cdki) with the biochemical ability to form a 
complex with cdk 4-6. This binding process inhibits cell cycle progression and tumor 
progression. P16 gene mutation, promoter methylation, and deletion are counted as the 
causes of its frequent inactivation [24]. Loss of p16 expression is not only reported in 
tumor development, but also for the prognosis of tumor progression [5,26].  
 
In this study, we compared the DNA methylation status in paired HCC and non-
cancerous liver tissues for a panel of 21 tumor-related genes. Among these selected genes, 
p16, RASSF1A, E-Cadherin, MSH2, CCND2, SEMA3B, SPINT2, SFN, MYC, 
MAGEA3B, FHIT, and MGMT were reported to have methylation rates higher than 40% 
for HCC [19, 27-30].   The other 9 genes: p14, p15, GATA4, NDRG4, OPCML, SEPT9, 
SFRP2, TFPI2, and ALX4 were documented to have elevated methylation in colon 
cancer tissues [31-34]. Using bisulfite deamination treatment and methylation-specific 
polymerase chain reaction (MSP) method, we obtained the distinct HCC methylation 
profiles and evaluated their combinational use for the detection of HCC. 
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5.2. Materials and methods 
 
5.2.1. Collection of clinical tissue specimen 
 
We analyzed 80 tissue samples, consisting HCC and paired non-HCC liver tissues as 
control, from 40 patients who underwent curative resection surgery between 2001 and 
2007. All patients were subjected to pathological diagnosis and classification for different 
stages. Informed consent was obtained before the study from each patient. A summary of 
the clinicopathological features is listed in Table 5.1. For all patients, liver tissue samples 
were collected from the cancerous and the adjacent non-cancerous surgical margin. The 
adjacent tissues included 16 cirrhotic samples and 24 normal samples. All of these tissues 
were stored as formalin-fixed paraffin-embedded (FFPE) samples. 
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HCC patients 
  
n=40 NO. of Patients  
Male 
Female 
32 
Female 8 
Age (average ± SD)                                                   50.5±8.2 
                                                                        50.5±8.2 Etiology  
HBV 8 
Tumor size 
>5cm 16 
<5cm 24 
Cirrhosis 
Yes 24 
No 16 
Nodules 
Yes 25 
No 15 
Stage 
I 2 
II 17 
II-III 8 
III 13 
Table 5.1, Clinical and pathological characters of 40 HCC patients 
involved in this study 
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5.2.2. DNA isolation from liver tissues 
 
Since all the tissue samples were fixed by formalin and embedded by paraffin, they were 
cut into 5 μm sections prior to xylene extraction. Every 6-7 sections of FFPE samples 
were incubated with 1.5 mL of xylene and vortexed for 30 min. Followed by the 
centrifugation at 10,000 rpm for 5 min, the supernatant was removed to a clean 
Eppendorf tube. These steps were repeated for 3 times by adding ethanol into the pellet to 
remove the residual xylene. At the end, the resulting tissue pellet was collected after the 
evaporation of ethanol residue.  
 
Genomic DNA automated extraction was performed on the Maxwell® 16 Instrument 
(Promega, Madison, WI) with Maxwell® 16 DNA Purification Kits.  Tissue pellet was 
lysed, purified, and washed by cell lysis solution, MagneSil PMPs, and wash buffer, 
respectively. 
 
5.2.3. Sodium bisulfite conversion 
 
Prior to sodium bisulfite conversion, DNA concentration was quantified by RT-PCR 
amplification. Standard unmethylated and methylated genomic DNA was purchased with 
CpGenome DNA modification Kit (Millipore, Billerica, MA) for establishing standard 
curve. Different concentration of standard DNA were obtained by serial dilution and then 
amplified with the β-actin (ACTB) primer: 5’ GGCGGCACCACCATGTACCCT 3’ and 
5’ AGGGGCCGGACTCGTCATACT 3’. Sample DNA concentration was calculated 
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utilizing the standard calibration curve of cycle numbers and log concentration. Based on 
these results, the final genomic DNA concentrations of all samples were normalized 
within the same concentration through dilution adjustment. 
 
Sodium bisulfite reaction was performed on cancerous, adjacent cirrhosis, and normal 
control DNA samples as well as standard unmethylated and methylated DNA samples 
using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA). Briefly, the 
bisulfite reagent was prepared as 5.5 mol/L sodium bisulfite in the mixture of M-Dilution 
buffer and M-Dissolving buffer (6:1, v/v). Every 100 ng DNA samples were mixed with 
50 μL bisulfite reagent. The reaction took 150 min in the following program: 0-10 min at 
95 °C, 10-150 min at 64 °C, and then cool down to 4 °C at the end of the reaction. The 
modified DNA sample was then desalted using KingFisher Flex Magnetic Particle 
Processors (Thermo Scientific, Asheville, NC). The whole purification consisted of 
sample binding, desulfonation, binding buffer wash, ethanol wash, and elution. The 
sample binding process utilized 200 μL EZ beads for each sample. The desulfonation step 
used 0.2 mmol/L NaOH in PEG binding buffer, and the ethanol wash used 80% ethanol 
and 100% ethanol with or without salts. At the end, the converted DNA sample was 
eluted in 10 mM Tris buffer and store at -20 °C for the further use.  
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5.2.4. DNA methylation analysis 
 
MSP amplifications of 21 genes including p16, RASSF1A, MSH2, CCND2, SEMA3B, 
SPINT2, SFN, MYC, MAGEA3B, FHIT, E-Cad, MGMT, p14, p15, GATA4, NDRG4, 
OPCML, SEPT9, SFRP2, TFPI2, and ALX4 were performed on MJ Research Chromo4 
Real Time PCR Instrument (Bio-Rad, Hercules, CA) and LightCycler 480 (Roche 
Diagnostics; Switzerland). The primer sequences of each locus for MSP were described 
in Table 5.2. The reaction mixture included 1 μL bisulfite-modified genomic DNA, 4 μL 
primer solution at 5 μmol/L, and 5 μL Type-it® HRM master mix (contains DNA 
polymerase, EvaGreen dye, optimized concentration of Q-solution, dNTPs, and MgCl2) 
(Qiagen,Valencia, CA) for a total volume of 10 μL. The following PCR program was 
applied: 95 °C denaturing for 10 min and 50 cycles of 95 °C for 45 s, annealing 
temperature for 30 s, and extension at 72 °C for 45 s.  
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Gene MSP primer 5'-3' 
Annealing 
Temperatu
re (°C) 
p16 (INK4A)  
F: TTATTAGAGGGTGGGGCGGATCGC 
66 R: CCACCTAAATCGACCTCCGACCG 
RASSF1A 
F: GTGTTAACGCGTTGCGTATC 
57 R: AACCCCGCGAACTAAAAACGA 
CCND2 
F: GGCGGATTT TAT CGTAGTCG 
62 R: CTCCACGCTCGA TCCTTCG 
SEMA3B 
F:  TGGTTAGGCGGGGTATTTTC 
58 R: TCAACAATAAAAACGAAAACG 
SPINT2 
F: CGGGCGTTTTTATATTGAAGGTTC 
60 R: ACGCCACCAACCGTTAAAATCTCG 
MYC 
F:  TAGAATTGGATCGGGGTAAA  
57 R:  CGACCGAAAATCAACGCGAAT 
SFN  
(has-mir-219-2) 
F:  TGGTAGTTTTTATGAAAGGCGTC 
58 R:  CCTCTAACCGCCCACCACG 
MAGEA3 
F: TTTGTTCGGAATTTAGGGTAGTATC 
60 R:  GTCGCTCGTTACTCAAAACG 
MSH2 
F:  TCG TGG TCG GAC GTC GTT C 
60 R:  CAA CGT CTC CTT CGA CTA CAC CG 
FHIT 
F:  GAAGGTAGGGGCGGGGAGGTAAGTT 
68 R:  CGTAAACGACGCCGACCCCACTA 
Table 5.2, The MSP primer sequences of 21 genes 
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Gene MSP primer 5'-3' 
Annealing 
Temperature 
(°C) 
E-Cadherin 
F: TAATTAGCGGTACGGGGGGC 
66 
R: CGAAAACAAACGCCGAATACG 
MGMT F: ATTTGGTGAGTGTTTGGGTCGTTTC 57 
R: AAAACGCACCTAAAACTCGCCC 
OPCML 
F: CGTTTAGTTTTTCGTGCGTTC 
62 
R: CGAAAACGCGCAACCGACG 
P15 
F: GCGTTCGTATTTTGCGGTT 
58 
R: CGTACAATAACCGAACGACCGA 
SFRP2 
F: GGGTCGGAGTTTTTCGGAGTTGCGC 
60 
R: CCGCTCTCTTCGCTAAATACGACTCG 
TFPI2 
F:  TTTCGTATAAAGCGGGTATTC 
57 
R:  ACGACCCGCTAAACAAAACG 
ALX4 
F: CGTTCGCGTTTTCGTTCGTCGTTTGC 
58 
R:  ACGACGAACCCTCCCGACTCTACG 
GATA4 
F: AGGTTAGTTAGCGTTTTAGGGTC 
60 
R:  ACGACGACGAAACCTCTCG 
NDRG4 
F:  TTTAGGTTCGGTATCGTTTCGC 
60 
R:  CGAACTAAAAACGATACGCCG 
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5.2.5. Specificity and sensitivity of MSP 
 
The specificity of the MSP assay was evaluated by detecting the bisulfite-modified 
standard unmethylated DNA and methylated DNA through high-resolution-melting 
(HRM) analysis repeatedly. The melting temperatures for each gene were recorded as 
reference for the patient sample analysis. Sensitivity of MSP was determined by mixing 
bisulfite-modified standard methylated DNA (1%) with standard unmethylated DNA 
(99%) together.  
 
5.2.6. Quantitative methylation analysis 
 
The quantitative methylation analysis was carried out on MJ Research Chromo4 Real 
Time PCR Instrument. Bisulfite-converted standard DNA sample of known concentration 
was serial diluted and amplified using bisulfite-converted ACTB primer. The standard 
curve prepared from this step was used for determining reference quantity of total 
DNA(Qtotal) amount for each patient sample. The amplification condition was as 
following: 95 °C denaturing for 10 min, 50 cycles of 95 °C for 45 s and 60 °C annealing 
for 30 s, and extension at 72 °C for 45 s. Patient samples that were negative for ACTB 
gene amplification were exclude from the study.  
 
The methylated DNA reference(QM) was determined by constructing the standard curve 
of bisulfite-converted standard methylated DNA in serial concentrations. The conditions 
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for the amplification were using the MSP primer and specific annealing temperature. In 
this case, only the converted methylated DNA can be amplified.  
 
5.3. Results  
 
5.3.1. Specificity and sensitivity of MSP method 
 
The specificity of the MSP methods on 21 genes was evaluated using standard 
unmethylated DNA as negative control and methylated DNA as positive control to ensure 
the completion of bisulfite conversion. In addition, two blank samples, one from the 
blank control added before the bisulfite conversion and the other added before the PCR 
reaction, were used to account for false positive. As shown in Fig. 5.2, this highly 
specific test on the SFN gene was illustrated in the PCR amplification and the subsequent 
melting curve analysis for standard methylated DNA and unmethylated DNA as well as a 
blank control. The selected primer and optimized PCR conditions ensured that only 
methylated DNA after bisulfite conversion could be amplified for all genes. The 
specificity of these MSP methods is high for all 21 genes.  
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Figure 5.2, The amplification results of standard methylated DNA, 1% 
methylated DNA, standard unmethylated DNA as negative control, and blank 
control are shown in RT-PCR (A) and melting curve analysis (B). 
A. 
B. 
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The sensitivity of the MSP methods was assessed by mixing 1% standard methylated 
DNA and 99% standard unmethylated DNA together. Repeated amplifications of the 
mixed sample were performed by RT-PCR. For most genes, the MSP methods could 
detect 1% methylation to ensure enough sensitivity of tests (Fig. 5.2).  
 
During the patient sample MSP analysis, control samples including negative and positive 
control, and two blank samples, as well as 1% standard methylated DNA were amplified 
on the same plate with patient samples. These controls ensured the completion of bisulfite 
reaction and the reliability of the results.  
 
5.3.2. Gene-specific promoter methylation analysis 
 
In epigenetic studies of HCC, the aberrant promoter methylation of p16, RASSF1A, E-
Cadherin, MSH2, CCND2, SEMA3B, SPINT2, SFN, MYC, MAGEA3B, FHIT, and 
MGMT was frequently reported in previous studies [19, 27-30]. We selected these genes 
for methylation screening. In addition, another nine genes including p14, p15, GATA4, 
NDRG4, OPCML, SEPT9, SFRP2, TFPI2, and ALX4, which were found to be highly 
hypermethylated in colon cancer and related to the tumorigenesis [31-34], were also 
examined in this study. For all the 40 pairs of matched cancerous and noncancerous liver 
tissue samples, 4 pairs of patient samples were found to have very low amount of DNA 
and they were excluded from the methylation profiling.  
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Among all the patient samples, 14 pairs of HCC cancerous and non-cancerous adjacent 
tissues were first randomly selected for the screening of all genes in the training phase, 
and then another 22 pairs of matched liver tissue samples were used for validating the 
screened genes. The reported highly methylated genes on colon cancer were found to 
have negative results for all HCC samples. In addition, the methylation rates on E-
Cadherin, MGMT, CCND2, MYC, and FHIT were very low on both cancerous and non-
cancerous tissues. For all other genes, the methylation rates were listed in Table 5. 3.  
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Table 5.3 The methylation profiles of ten tumor suppressor genes in the screening test 
 
 
 
Gene 
Cancerous liver tissue 
 Adjacent 
non-cancerous tissue 
No. of samples 
methylated 
Methylation 
rates 
 
No. of samples 
methylated 
Methylation  
rates 
P16 15(36) 41%  2(36) 6% 
RASSF1A 32(36) 88%  10(36) 28% 
SPINT2 23(36) 57%  2(36) 6% 
SFN 33(36) 92%  32(36) 89% 
SEMA3B 24(36) 67%  20(36) 56% 
MAGEA3 22(36) 61%  24(36) 67% 
MSH2 22(36) 61%  19(36) 53% 
CCND2 2(14) 14%  1(14) 7% 
MYC 0(14) 0%  1(14) 7% 
FHIT 1(14) 7%  3(14) 21% 
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Based on these results from the screening test, p16, RASSF1A, SPINT2, SFN, SEMA3B, 
MAGEA3, and MSH2 showed relatively high methylation frequencies on HCC 
cancerous tissues. As a result, these seven genes were further selected for the validation 
analysis on the other 22 pairs of samples (Table 5. 3). For genes p16, RASSF1A, and 
SPINT2, they showed significant higher methylation rates in cancerous samples over 
noncancerous samples. However, we found that the methylation frequencies of SFN, 
SEMA3B, MAGEA3, and MSH2 were also high in adjacent noncancerous sample and 
their methylation profiles were not adequate to distinguish these two groups.  
 
The high methylation frequencies in non-cancerous tissues on SFN, SEMA3B, MAGEA3, 
and MSH2 may be related to the field cancerization of HCC, which initiates the 
malignancy with the accumulation of epigenetic and genetic damages on several tumor 
suppressor genes [35, 36]. To test this explanation, we examined the methylation status of 
the aforementioned seven genes in the validation study from 36 pairs of HCC and their 
corresponding non-cancerous tissues. Four possibilities of methylation status in paired 
samples from the same patient were proposed: 1) positive methylation in both cancerous 
and non-cancerous tissues as C(+)/NC(+); 2) positive methylation in cancerous tissue but 
negative in non-cancerous tissue as C(+)/NC(-); 3) negative methylation in both cancerous 
and non-cancerous tissues as C(-)/NC(-); 4) negative methylation in cancerous tissue but 
positive in non-cancerous tissue as C(-)/NC(+). The results after the comparison of each 
gene showed that most tissue pairs had accordant alterations with the methylation status 
of C(+)/NC(+) at 40%, C(+)/NC(-) at 25%, and C(-)/NC(-) at 24%. The discordant methylation 
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appeared in 3% tissue pairs as C(-)/NC(+)  for genes p16, RASSF1A, SEMA3B, MAGEA3, 
and MSH2 (Table 5.4).  
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Table 5.4. Methylation status in paired cancerous and non-cancerous samples (n=36) 
from the same patient 
 
Genes C(-)/NC(-) C(-)/NC(+) C(+)/NC(-) C(+)/NC(+) 
P16 20(56%) 1(3%) 14(39%) 1(3%) 
RASSF1A 3(8%) 1(3%) 23(64%) 9(25%) 
SPINT2 13(4%) 0(0%) 21(58%) 2(6%) 
SFN 3(8%) 0(0%) 1(3%) 32(89%) 
SEMA3B 10(28%) 2(6%) 6(17%) 18(50%) 
MAGEA3 11(31%) 3(8%) 1(3%) 21(58%) 
MSH2 13(36%) 1(3%) 4(11%) 18(50%) 
     
Average% 24% 3% 25% 40% 
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5.3.3. Quantitative methylation analysis 
 
Although the promoter methylation on SFN, SEMA3B, MAGEA3, and MSH2 were high 
in HCC patient samples, the MSP analysis cannot differentiate the non-cancerous and 
cancerous tissue with the assistance of the melting curves. To obtain the quantitative 
information, we further performed RT-PCR methylation analysis of these three genes on 
36 pairs of matched samples. The quantitative results were expressed as methylation 
percentage, which was determined by the following equation:  
 
QM and QTotal were the reference methylated and total DNA quantity, respectively. As 
shown in Figure 5.3, Standard curves were established to determine QM and QTotal. 
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A.  
B.  
Figure 5.3, Standard curves constructed for quantifying methylated DNA 
for gene SFN (A) and total DNA using primer ACTB (B) 
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As summarized in Table 5.5, the quantitative results in 36 pairs of matched HCC tissues 
showed higher methylation percentage on gene SFN and MSH2 for cancerous samples 
comparing with the non-cancerous ones. The methylation percentage was low in both 
tissues for gene SEMA3B, and it appeared to be higher in non-cancerous tissue than in 
cancerous tissue for gene MAGEA3. Currently, the cut-off value cannot be set to define 
the cancerous and non-cancerous tissues based on their methylation percentage.  
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Table 5.5 The methylation percentage of 4 genes on 36 pairs of HCC 
cancerous/non-cancerous samples 
 
 
Genes 
HCC Cancerous 
Samples 
 
(Average ± S.D) 
Non-Cancerous 
Samples 
 
(Average ± S.D) 
N 
SFN 
76%±39% 37%±25% 32 
SEMA3B 
14%±8% 7%±5% 18 
MAGEA3 
59%±17% 94%±26% 21 
MSH2 
57%± 28%, 21%±19% 18 
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5.4. Discussion 
 
Epigenetic analysis of promoter methylation plays an important role in the process of 
tumorigenesis and biomarker discovery for disease diagnosis. Recent studies have 
demonstrated that HCC had a high frequency of promoter methylation of multiple genes 
[18-19, 27-30]. However, many issues regarding the comprehensive methylation profile 
of a large pool of tumor-associated genes and the mechanisms of epigenetic phenomena 
in cancer progress remain elusive. In this study, we decided to investigate the promoter 
methylation status of multiple genes including p16, RASSF1A, E-Cadherin, MSH2, 
CCND2, SEMA3B, SPINT2, SFN, MYC, MAGEA3B, FHIT, MGMT, p14, p15, 
GATA4, NDRG4, OPCML, SEPT9, SFRP2, TFPI2, and ALX4. These genes are 
involved in different molecular pathways of carcinogenesis such cell-cycle regulatory 
(p16, p14, and p15), apoptosis (RASSF1A, SEMA3B and FHIT), cell adhesion (E-
Cadherin), and DNA repair (MGMT). Understanding their functions in the advance 
tumor stages of HCC provides the ability to predict the premalignant conditions for early 
diagnosis.  
 
The current study has successfully identified altered methylation status on several genes 
using the developed quantitative methylation profiling method. Sodium bisulfite reacted 
with the methylated CpG site specifically, enabling the discrimination of methylated 
DNA with unmethylated DNA by methylation-specific PCR. Among the 21 tested genes, 
p16, RASSF1A, SPINT2, SFN, SEMA3B, MAGEA3, and MSH2 had higher frequencies 
of promoter methylation in the training phase, in which 14 pairs of cancerous versus non-
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cancerous adjacent tissues were used. Although hypermethylation of E-Cadherin, 
CCND2, MYC, FHIT, and MGMT in HCC was reported in previous studies for HCC 
[28-30], it was not observed in the present study. Interestingly, the methylation status of 
all colon cancer related genes including p14, p15, GATA4, NDRG4, OPCML, SEPT9, 
SFRP2, TFPI2, and ALX4 showed negative results for all HCC samples. This may be 
explained by that the molecular functions of these genes in carcinogenesis are specific to 
colon cancer, rather than HCC.  
 
Based on the results of training phase, all the genes with low methylation rates in HCC 
samples were eliminated, leaving seven genes for the validation and further screening on 
another 22 pairs of matched samples. The methylation status of these seven genes were 
profiled and shown that high methylation frequency of both cancerous tissue and adjacent 
non-cancerous tissue for the majority of sample pairs. This phenomenon suggested field 
cancerization in the surgical margin. For gene SPINT2 and SFN, their methylation status 
was accordant in all the sample pairs, revealing the monoclonal expansion model in the 
early cancer event. The discordant methylation status of p16, RASSF1A, SEMA3B, 
MAGEA3, and MSH2 may result from the polycolonal origins of HCC. These results 
indicated the complicated origins in hepatocarcinogenesis, involving both monoclonal 
and polyclonal expansion of preneoplastic cells. 
 
Due to the silenced gene expression in cancerous and non-cancerous pairs for most 
hypermethylated genes, the methylation frequencies were not adequate to predict the 
early event of HCC. We developed the comparative quantification assay for SFN, 
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SEMA3B, MAGEA3, and MSH2 to separate HCC cancerous and non-cancerous samples. 
SFN and MSH2 demonstrated higher methylation percentage compared to other genes. 
However, adequate cut-off value to define cancerous from non-cancerous tissues was not 
available for these two genes. These results may be due to the fact that HCC sample pairs 
used in the study were mainly from advanced stage, and the field cancerization caused 
the accumulative epigenetic changes in the surgical margins.  
 
In conclusion, we examined the gene-specific alterations through promoter methylation 
profiling on 21 genes using bisulfite conversion and MSP. With the comparison of HCC 
cancerous and non-cancerous tissues, frequent CpG island hypermethylation was found 
for p16, RASSF1A, and SPINT2. In addition, we observed the consistent methylation 
status in cancerous and adjacent non-cancerous tissue for other hypermethylated genes 
SFN and MSH2, resulted from field cancerization of HCC. In the future, the quantitative 
methylation assays will be performed on early stage of HCC samples to better assess the 
ability of these genes for its early screening. The results from the present study supported 
that the DNA methylation could be an important event during carcinogenesis and a 
potential biomarker for HCC diagnosis. 
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